

Bibliography

Abbott, F. M. (2016), "Excessive Pharmaceutical Prices and Competition Law: Doctrinal Development to Protect Public Health", *UC Irvine Law Review*, 6(3): 281–320.

Abbott, F. M. and Correa, C. M. (2007), "World Trade Organization Accession Agreements: Intellectual Property Issues", FSU College of Law, Law, Business and Economics Paper, Geneva: Quaker United Nations Office.

Abbott, F. M. and Reichman, J. H. (2007), "The Doha Round's public health legacy: Strategies for the production and diffusion of patented medicines under the amended TRIPS provisions", *Journal of International Economic Law* 10(4): 921–987.

Aboy, M., Crespo, C., Liddell, K., Liddicoat, J. and Jordan, M. (2018), "Was the *Myriad* decision a surgical strike on isolated DNA patents, or does it have wider impacts?", *Nature Biotechnology* 36: 1146–1149.

Adlung, R. (2009), "Services Liberalization from a WTO/GATS Perspective: In Search of Volunteers", Staff Working Paper ERSD–2009–05, Geneva: WTO.

Adlung, R. (2010), "Trade in healthcare and health insurance services: WTO/GATS as a supporting actor(?)", *Intereconomics* 45(4): 227–238.

African Union, "African Union Ministers of Health adopt treaty for the establishment of the African Medicines Agency Treaty to be submitted to the Specialised Technical Committee on Justice and Legal Affairs later on this year", press release, 20 May 2018, available at: <https://au.int/en/pressreleases/20180520/african-union-ministers-health-adopt-treaty-establishment-african-medicines>.

Aitken, M. and Kleinrock, M. (2017), *Lifetime Trends in Biopharmaceutical Innovation: Recent Evidence and Implications*, Parsippany (NJ): IQVIA Institute for Human Data Science.

Albrecht, B., Menu, P., Tsao, J. and Webster, K. (2016), *The Next Wave of Innovation in Oncology*, McKinsey & Company, available at: <https://www.mckinsey.com/~media/McKinsey/Industries/Healthcare%20Systems%20and%20Services/Our%20Insights/The%20next%20wave%20of%20innovation%20in%20oncology/The-next-wave-of-innovation-in-oncology.ashx>.

Ali, F., Rajagopal, S., Mustafa, M. and Prabhu, C. (2017), "Rejected in India: What the Indian Patent Office Got Right on Pharmaceuticals Patent Applications (2009–2016)", available at: <https://www.accessibsa.org/media/2017/12/Rejected-in-India.pdf>.

Allee, T. and Peinhardt, C. (2011), "Contingent Credibility: The Impact of Investment Treaty Violations on Foreign Direct Investment", *International Organization Journal* 65(3): 401–432.

Amanam, I. U., Gardner, A. B., Young-Lin, N. and Chan, J. K. (2016), "The increase in FDA-approved novel cancer drugs over the last 5 years: What factors are involved?", *Journal of Clinical Oncology* 34(15): e14111.

Anderson, R. (2014), "Pharmaceutical industry gets high on fat profits", *BBC News*, online version, 6 November 2014, available at: <https://www.bbc.com/news/business-28212223>.

Anderson, R. D., Kovacic, W. E. and Müller, A. C. (2011), "Ensuring Integrity and Competition in Public Procurement Markets: A Dual Challenge for Good Governance", in Arrowsmith, S. and Anderson, R. D. (eds.), *The WTO Regime on Government Procurement: Challenge and Reform*, Cambridge: Cambridge University Press.

Anderson, R. D., Kovacic, W. E., Müller, A. C. and Sporysheva, N. (2018), "Competition Policy, Trade and the Global Economy: Existing WTO Elements, Commitments in Regional Trade Agreements, Current Challenges and Issues for Reflection", Staff Working Paper ERSD 2018-12, Geneva: WTO.

Anderson, R. D., Müller, A. C. and Pelletier, P. (2016), "Regional Trade Agreements and Procurement Rules: Facilitators or Hindrances?" A version was published as Robert Schuman Centre for Advanced Studies (RSCAS) Research Paper No. RSCAS 2015/81, December 2015.

Anderson, R. D., Pires de Carvalho, N. and Taubman, A. (eds.) (2020), *Competition Policy and Intellectual Property in Today's Global Economy*, Cambridge: Cambridge University Press.

Aranze, J. (2017), "Italian court upholds Aspen excessive pricing decision", *Global Competition Review*, 3 August 2017, available at: <https://globalcompetitionreview.com/article/1145288/italian-court-upholds-aspen-excessive-pricing-decision>.

Årdal, C., Findlay, D., Savic, M., et al. (2018), "Revitalizing the antibiotic pipeline: Stimulating innovation while driving sustainable use and global access", available at: <http://drive-ab.eu/wp-content/uploads/2018/01/DRIVE-AB-Final-Report-Jan2018.pdf>.

Armstrong, I. (2019), "Immunotherapy patents: Why CAR-T is driving up patent activity", *World Intellectual Property Review*, online version, 17 September 2019.

Association de lutte contre le SIDA (2018), *Diagnosis and monitoring of hepatitis C (HCV) in Morocco: Current Status and strategies for universal access*, available at: <https://www.alcs.ma/1282-diagnosis-and-monitoring-of-hepatitis-c-hcv-in-morocco>.

Avorn, J. (2015), "The \$2.6 billion pill – Methodologic and policy considerations", *New England Journal of Medicine* 372: 1877–1879.

Baghdadi-Sabeti, G. and Serhan, F. (2010), "WHO Good Governance for Medicines Programme: An Innovative Approach to Prevent Corruption in the Pharmaceutical Sector", World Health Report (2010) Background Paper 25, Geneva: WHO.

Bagley, N., Chandra, A., Garthwaite, C. and Stern, A.D. (2018), "It's Time to Reform the Orphan Drug Act", *NEJM Catalyst*, 19 December 2018.

Balasegaram, M., Kolb, P., McKew, J., Menon, J., Olliaro, P., Sablinski, T., et al. (2017), "An open source pharma roadmap", *PLoS Medicine* 14(4): e1002276.

Ball, D. (2011), "The Regulation of Mark-ups in the Pharmaceutical Supply Chain", WHO/HAI Project on Medicine Prices and Availability, Review Series on Pharmaceutical Pricing Policies and Interventions, Working Paper 3, Geneva: WHO and HAI.

- Batson, A. (2016), Global vaccine market. Global Vaccine and Immunization Research Forum. March 2016, available at: https://www.who.int/immunization/research/forums_and_initiatives/1_ABatson_Global_Vaccine_Market_gvirf16.pdf.
- Beall, R. F. and Attaran, A. (2016), *Global Challenges Report: Patent-based Analysis of the World Health Organization's 2013 Model List of Essential Medicines*, Geneva: WIPO.
- Beall, R. F. and Kesselheim, A. S. (2018), "Tertiary patenting on drug-device combination products in the United States", *Nature Biotechnology* 36: 142–145.
- Beall, R. F., Darrow, J. J. and Kesselheim, A. S. (2019), "Patent term restoration for top-selling drugs in the United States", *Drug Discovery Today* 24(1): 20–25.
- Beall, R. F., Nickerson, J. W., Kaplan, W. A. and Attaran, A. (2016), "Is patent 'evergreening' restricting access to medicine/device combination products?", *PLoS ONE* 11(2): e0148939.
- Ben-Ayre, E., Schiff, E., Hassan, E., Mutafoglu, K., Lev-Ari, S., Steiner, M. et al. (2012), "Integrative oncology in the Middle East: From traditional herbal knowledge to contemporary cancer care", *Annals of Oncology* 23(1): 211–221.
- Bennett, M. R. (1999), "One hundred years of adrenaline: The discovery of autoreceptors", *Clinical Autonomic Research* 9(3): 145–159.
- Beran, D., Ewen, M. and Laing, R. (2016), "Constraints and challenges in access to insulin: A global perspective", *The Lancet Diabetes and Endocrinology* 4(3): 275–285.
- Berndt, E. and Aitken, M. (2011), "Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation," *International Journal of the Economics of Business* 18(2): 177-201.
- Bertram, M. Y., Lauer, J. A., De Joncheere, K., Edejer, T., Hutubessy, R., Kieny, M.-P. et al. (2016), "Cost-effectiveness thresholds: Pros and cons", *Bulletin of the World Health Organization* 94(12): 925–930.
- Beyer, P. (2012), "Developing Socially Responsible Intellectual Property Licensing Policies: Non-Exclusive Licensing Initiatives in the Pharmaceutical Sector", in de Werra, J. (ed.), *La propriété intellectuelle dans l'industrie pharmaceutique: Intellectual Property in the Pharmaceutical Industry*, Geneva: Schulthess Verlag.
- Black, L. L. (2017), "Patenting and protecting personalized medicine innovation post-Mayo, Myriad, and Limelight", *North Carolina Law Review* 95(2): 493–522.
- Blackstone, E. A. and Fuhr, J. P. (2013), "The economics of biosimilars", *American Health & Drug Benefits* 6(8): 469–478.
- Bloom, N., Jones, C. I., Van Reenen, J. and Webb, M. (2017), "Are Ideas Getting Harder to Find?", Working Paper No. w23782, Cambridge (MA): National Bureau of Economic Research (NBER).
- Bond, R. S. and Lean, D. F. (1977), *Sales, Promotion, and Product Differentiation in Two Prescription Drug Markets: Staff Report to the Federal Trade Commission*, Washington, DC: Federal Trade Commission.
- Bosco, J. and Chance, K. (2013), "Biosimilars: Stakeholders' Changing Expectations and the Role of Real-World Evidence", online presentation, Quintiles.
- Bowers, S. and Cohen, D. (2018), "How lobbying blocked European safety checks for dangerous medical implants", *BMJ* 363: k4999.
- Brazil, R. (2018), "Navigating Drug Discovery with High-Throughput Screening", *Drug Discovery*, online version, 21 February 2018, available at: <https://www.technologynetworks.com/drug-discovery/articles/navigating-drug-discovery-with-high-throughput-screening-297350>.
- Bregonje, M. (2005), "Patents: A unique source for scientific technical information in chemistry related industry?", *World Patent Information* 27(4): 309–315.
- Brett, A. S. (2010), "Spotlight on colchicine: The Colcrys controversy", *NEJM Journal Watch*.
- Brigden, G., Castro, J. L., Ditiu, L., Gray, G., Hanna, D., Low, M. et al. (2017), "Tuberculosis and antimicrobial resistance – new models of research and development needed", *Bulletin of the World Health Organization* 95(5): 315.
- Brigden G., Hewison, C. and Varaine, F. (2015), "New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid", *Infection and Drug Resistance* 8: 367–378.
- Bud, R. (2008), "Upheaval in the moral economy of science? Patenting, teamwork and the World War II experience of penicillin", *History and Technology* 24: 173–190.
- Budish, E., Roin, B. N. and Williams, H. (2015), "Do firms underinvest in long-term research? Evidence from cancer clinical trials", *American Economic Review* 105(7): 2044–2085.
- Cameron, A. and Laing, R. (2010), "Cost Savings of Switching Private Sector Consumption from Originator Brand Medicines to Generic Equivalents", World Health Report (2010) Background Paper No. 35, Geneva: WHO.
- Cameron, A., Ewen, N., Ross-Degnan, D., Ball, D. and Laing, R. (2009), "Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis", *The Lancet* 373(9659): 240–249.
- Cameron, A., Roubos, I., Ewen, M., Mantel-Teeuwisse, A. K., Leufkens, H. G. M. and Laing, R. O. (2011), "Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries", *Bulletin of the World Health Organization* 89(6): 412–421.
- Campaign for Access to Essential Medicines (2011), *Untangling the Web of Antiretroviral Price Reductions*, 14th Edition, Geneva: Médecins Sans Frontières.
- Capra International Ltd (2016), *Comprehensive Evaluation of the Implementation of the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property: Corporate Evaluation Commissioned by the WHO Evaluation Office*, Cumberland, Ontario: Capra International and WHO.
- Caro de Sousa, P. (2019), "Excessive Pricing in Pharmaceutical Markets", *Competition Policy International*, online version, 20 January 2019, available at: <https://www.competitionpolicyinternational.com/excessive-pricing-in-pharmaceutical-markets/>.
- Cassier, M. and Sinding C. (2008), "'Patenting in the public interest:' administration of insulin patents by the University of Toronto", *History and Technology* 24(2): 153–171.

- Cassini et al., 2019. "Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis", *The Lancet Infectious Diseases* 19(1): 56–66, available at: [http://dx.doi.org/10.1016/S1473-3099\(18\)30605-4](http://dx.doi.org/10.1016/S1473-3099(18)30605-4).
- de Chadarevian. S. (2011), "The Making of an Entrepreneurial Science: Biotechnology in Britain, 1975-1995", *Isis* 102(4): 601–633.
- Chakradhar, S. and Khamsi, R. (2017), "Angst about exclusivity: The potential cost of incentivizing makers of generic drugs", *Nature Medicine* 23(10): 1114–1116.
- Chandrasekharan S., Amin, T., Kim, J., Furrer, E., et al. "Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing-country vaccine manufacturers", *Vaccine* 33(46): 6366–6370.
- Chapman, N., Doubell, A., Oversteegen, L., Chowdhary, V., Rugarabamu, G., Zanetti, R. et al. (2017), *G-FINDER 2017: Neglected Disease Research and Development: Reflecting on a Decade of Global Investment*, Sydney: Policy Cures Research.
- Chaudhuri, S., Goldberg, P. K. and Jia, P. (2006), "Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India", *American Economic Review* 96(5): 1477–1514.
- Cheever, M. A. and Higano, C. S. (2011), "PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine", *Clinical Cancer Research* 17: 3520–3526.
- Cherny, N., Sullivan, R., Torode, J., Saar, M. and Eniu, A. (2016), "ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe", *Annals of Oncology* 27(8): 1423–1443.
- Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y. et al. (2017), "ESMO-Magnitude of Clinical Benefit Scale version 1.1", *Annals of Oncology* 28: 2340–2366.
- Cherny, N. I., Sullivan, R., Torode, J., Saar, M. and Eniu, A. (2017), "ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe", *Annals of Oncology* 28(11): 2633–2647.
- Chien, C. (2003), "Cheap Drugs at What Price to Innovation: Does the Compulsory Licensing of Pharmaceuticals Hurt Innovation?", *Berkeley Technology Law Journal* 18(3): 853–907.
- Chopra, R. and Lopes, G. (2017), "Improving access to cancer treatments: The role of biosimilars", *Journal of Global Oncology* 3(5): 596–610.
- Christie, A.F., Dent, C., McIntyre, P., Wilson, L., et al. (2013), "Patents Associated with High-Cost Drugs in Australia", *PLoS ONE* 8(4): e60812, available at: <https://doi.org/10.1371/journal.pone.0060812>.
- Cleary, E. G., Beierlein, J. M., Khanuja, N. S., McNamee, L. M. and Ledley, F. D. (2018) Contribution of NIH funding to new drug approvals 2010–2016. *Proceedings of the National Academy of Sciences of the United States of America* 115(10): 2329–2334.
- Clendinen, C., Zhang, Y., Warburton, R. N., and Light, D. W. (2016), "Manufacturing costs of HPV vaccines for developing countries", *Vaccine* 34(48): 5984–5989.
- Cockburn, I. M. (2006), "Is the Pharmaceutical Industry in a Productivity Crisis?", in Jaffe, A. B., Lerner, J. and Stern, S. (eds.), *Innovation Policy and the Economy, Volume 7*, Cambridge (MA): National Bureau of Economic Research (NBER).
- Cockburn, I. M., Lanjouw, J. O. and Schankerman, M. (2016), "Patents and the global diffusion of new drugs", *American Economic Review* 106(1): 136–164.
- Cohen, J. (2017), "New CRISPR tool can detect tiny amounts of viruses", *Science*, online version, 13 April 2017.
- Cohen, W. M., Nelson, R. R. and Walsh, J. P. (2000), "Protecting Their Intellectual Assets: Appropriability Conditions and Why US Manufacturing Firms Patent (or Not)", Working Paper No. 7552, Cambridge (MA): National Bureau of Economic Research (NBER).
- Coller, B.G., Blue, J., Das, R., et al. (2017), "Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic", *Vaccine* 35: 4465–4469.
- Comanor, W. S. (1986), "The political economy of the pharmaceutical industry", *Journal of Economic Literature* 24(3): 1178–1217.
- Comanor, W. S. and Scherer, F. M. (2013), "Mergers and innovation in the pharmaceutical industry", *Journal of Health Economics* 32(1): 106–113.
- Commission on Health Research for Development (1990), *Health Research: Essential Link to Equity in Development*, Oxford: Oxford University Press.
- Commission on Intellectual Property Rights, Innovation and Public Health (CIPRH) (2006), *Public Health, Innovation and Intellectual Property Rights: Report of the Commission on Intellectual Property Rights, Innovation and Public Health*, Geneva: WHO.
- Conley, J. M., Cook-Deegan, R. and Lázaro-Muñoz, G. (2014), "Myriad after Myriad: The proprietary data dilemma", *North Carolina Journal of Law and Technology* 15(4): 597–637.
- Conner-Simons, A. (2017), "Using artificial intelligence to improve early breast cancer detection", *MIT News*, online version, 16 October 2017.
- Contreras, J. L. and Sherkow, J. S. (2017), "CRISPR, surrogate licensing, and scientific discovery", *Science* 355(6326): 698–700.
- Copenhagen Economics (2018), *Study on the Economic Impact of Supplementary Protection Certificates, Pharmaceutical Incentives and Rewards in Europe: Final Report*, Brussels: European Commission.
- Cornell University, INSEAD and WIPO (2019), *Global Innovation Index 2019: Creating Healthy Lives – The Future of Medical Innovation*, 12th Edition, Dutto, S., Lanvin, B. and Wunsch-Vincent, S. (eds.), Ithaca (NY), Fontainebleau and Geneva: Cornell University, INSEAD and WIPO.
- Cornish, W., Llewelyn, D. and Aplin, T. (2019), *Intellectual Property: Patents, Copyright, Trademarks & Allied Rights*, 4th Edition, London: Sweet and Maxwell.
- Correa, C. (2007), *Guidelines for the Examination of Pharmaceutical Patents: Developing a Public Health Perspective: A Working Paper*, Geneva: ICTSD, WHO and UNCTAD.

- Correa, C. M. (2004), "Implementation of the WTO General Council Decision on Paragraph 6 of the DOHA Declaration on the TRIPS Agreement and Public Health", Health Economics and Drugs Series No. 016, Geneva: WHO.
- Correa, C. M. (2016), *Guidelines for Pharmaceutical Patent Examination: Examining Pharmaceutical Patents from a Public Health Perspective*, New York: United Nations Development Programme (UNDP).
- Costa Chaves, B., Gaspar Britto, W. and Fogaça Vieira, M. (2017), *MERCOSUR-EU Free Trade Agreement: Impact Analysis of TRIPS-Plus Measures Proposed by the EU on Public Purchases and Domestic Production of HIV and Hepatitis C Medicines in Brazil*, available at: <https://www.accessibsa.org/media/2018/01/Mercosur-EU-Free-Trade-Agreement-HIV-Hepatitis-C.pdf>.
- Cotropia, C. A. (2008), "Compulsory Licensing Under TRIPS and the Supreme Court of the United States' Decision in eBay v. MercExchange", in Takenaka, T. and Moufang, R. (eds.), *Patent Law: A Handbook of Contemporary Research*, Edward Elgar Publishing Co, available at: <https://ssrn.com/abstract=1086142>.
- Council for International Organizations of Medical Sciences (CIOMS) (2016), *International Ethical Guidelines for Health-related Research Involving Humans*, Geneva: CIOMS.
- Creese, A. (2011), "Sales Taxes on Medicines", WHO/HAI Project on Medicine Prices and Availability, Review Series on Pharmaceutical Pricing Policies and Interventions, Working Paper 5, Geneva: WHO and HAI.
- Cross, R. W., Mire, C. E., Feldmann, H. and Geisbert, T. W. (2018), "Post-exposure treatments for Ebola and Marburg virus infections", *Nature Reviews Drug Discovery* 17: 413–434.
- Crow, D. (2017), "Scientists shrug off failures in hunt for Alzheimer's treatments", *Financial Times*, online version, 26 November 2017, available at: <https://www.ft.com/content/8d0db012-cda0-11e7-b781-794ce08b24dc>.
- Crowe, K. (2017), "Provinces spent \$43M on preemie drug experts say can be made for a fraction of the cost", *CBC News*, online version, 7 April 2017.
- Daniel, M. G., Pawlik, T. M., Fader, A. N., Esnaola, N. F. and Makary, M. A. (2016), "The Orphan Drug Act: Restoring the mission to rare diseases", *American Journal of Clinical Oncology* 39(2): 210–213.
- Danzon, P. M., Mulcahy, A. W. and Towse, A. K. (2015), "Pharmaceutical pricing in emerging markets: Effects of income, competition, and procurement", *Health Economics* 24(2): 238–252.
- Daulaire, N., Bang, A., Tomson, G., Kalyango, J. N. and Cars, O. (2015), "Universal access to effective antibiotics is essential for tackling antibiotic resistance", *Journal of Law, Medicine & Ethics* 43(3): 17–21.
- Davis, C., Naci, H., Gurpinar, E., Poplavska, E., Pinto, A. and Aggarwal, A. (2017), "Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: Retrospective cohort study of drug approvals 2009–13", *BMJ* 359: j4530.
- Deak, D., Outtersson, K., Powers, J. H. and Kesselheim, A. S. (2016), "Progress in the fight against multidrug-resistant bacteria? A review of U.S. Food and Drug Administration-approved antibiotics, 2010–2015", *Annals of Internal Medicine* 165(5): 363–372.
- Deloitte (2018), *2018 Global Life Sciences Outlook: Innovating Life Sciences In the Fourth Industrial Revolution: Embrace, Build, Grow*, available at <https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-ls-outlook-2018.pdf>.
- Deloitte (2019), *2019 Global Life Sciences Outlook: Focus and Transform: Accelerating Change in Life Sciences*, available at <https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-ls-outlook-2019.pdf>.
- Deloitte Centre for Health Solutions (2018), *Unlocking R&D Productivity: Measuring the Return from Pharmaceutical Innovation 2018*, London: Deloitte.
- Diependaele, L., Cockbain, J. and Sterckx, S. (2017), "Raising the barriers to access to medicines in the developing world – the relentless push for data exclusivity", *Developing World Bioethics* 17(1): 11–21.
- DiMasi, J. A., Grabowski, H. G. and Hansen, R.W. (2016), "Innovation in the pharmaceutical industry: New estimates of R&D costs", *Journal of Health Economics* 47: 20–33.
- DiMasi, J. A., Hansen, R. W. and Grabowski, H. G. (2003), "The price of innovation: New estimates of drug development costs", *Journal of Health Economics* 22: 151–185.
- DiMasi, J. A., Hansen, R. W., Grabowski, H. G. and Lasagna, L. (1991), "Cost of innovation in the pharmaceutical industry", *Journal of Health Economics* 10(2): 107–142.
- Dong, J. and Mirza, Z. (2016), "Supporting the production of pharmaceuticals in Africa", *Bulletin of the World Health Organization* 94: 71–72.
- Dora, S., Khanna, D., Luo, Y., Poon, L. and Schweizer, C. (2017), *Medtech May Be Emerging Markets' Next New Thing*, Boston Consulting Group, available at: <https://www.bcg.com/en-ch/publications/2017/globalization-medical-devices-technology-medtech-may-be-emerging-markets-next-new-thing.aspx>.
- Dreyfuss, R. C., Nielsen, J. and Nicol, D. (2018), "Patenting nature—a comparative perspective", *Journal of Law and the Biosciences* 5(3): 550–589.
- Driehaus, J. (2012), "Patent Landscape in Molecular Diagnostics", in Storz, U., Flasche, W., and Driehaus, J. (eds.), *Intellectual Property Issues*, Berlin, Heidelberg: Springer: 73–106.
- Drugs for Neglected Diseases initiative (DNDi) (2014), *An Innovative Approach to R&D for Neglected Patients: Ten Years of Experience & Lessons Learned by DNDi*, Geneva: DNDi.
- Drugs for Neglected Diseases initiative (DNDi) (2019), *15 Years of Needs-Driven Innovation for Access: Key Lessons, Challenges, and Opportunities for the Future*, Geneva: DNDi.
- Duggan, M. and Goyal, A. (2012), "Pharmaceutical Patents and Prices: A Preliminary Empirical Assessment Using Data from India", Policy Research Working Paper No. 6063, Washington, DC: World Bank.

- Ederigton, J. and Rutta, M. (2016), "Non-Tariff Measures and the World Trading System," World Bank Policy Research Paper, available at: <http://documents.worldbank.org/curated/en/882991467989523068/pdf/WPS7661.pdf>.
- Elks, S. (2018), "Drug buyers' clubs aim to tackle HIV prevention 'crisis'", Thomson Reuters Foundation News, 3 December 2018, available at: <http://news.trust.org/item/20181130235707-qho8y/>.
- Espin, J., Rovira, J. and Oly de Labry, A. (2011), "External Reference Pricing", WHO/HAI Project on Medicine Prices and Availability, Review Series on Pharmaceutical Pricing Policies and Interventions, Working Paper 1, Geneva: WHO and HAI.
- European Commission (2009a), *Communication from the Commission: Executive Summary of the Pharmaceutical Sector Inquiry Report*, available at: https://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/communication_en.pdf.
- European Commission (2009b), *Pharmaceutical Sector Inquiry: Final Report: Adoption date: 8 July 2009*, available in two parts at <https://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/>.
- European Commission (2014a), "German company wins EU's €2 million inducement prize for innovative vaccine technology", press release, 10 March 2014, available at: https://europa.eu/rapid/press-release_IP-14-229_en.htm?locale=EN.
- European Commission (2014b), Medical Countermeasures That Could Be Procured in Common Under the Joint Procurement Agreement, available at: https://ec.europa.eu/health/sites/health/files/preparedness_response/docs/jpa_note_scope_en.pdf.
- European Commission (2017), "Antitrust: Commission opens formal investigation into Aspen Pharma's pricing practices for cancer medicines", press release, 15 May 2017, available at: http://europa.eu/rapid/press-release_IP-17-1323_en.htm.
- European Commission (2018a), *Innovative Payment Models for High-cost Innovative Medicines: Report of the Expert Panel on Effective Ways of Investing in Health (EXPH)*, Luxembourg: Publications Office of the European Union.
- European Commission (2018b), *EU R&D Scoreboard: The 2018 EU Industrial R&D Investment Scoreboard*, Luxembourg: Publications Office of the European Commission.
- European Commission (2019a), *Competition Enforcement in the Pharmaceutical Sector (2009-2017): European Competition Authorities Working Together for Affordable and Innovative Medicines*, Luxembourg: Publications Office of the European Union.
- European Commission (2019b), *Report on the EU Customs Enforcement of Intellectual Property Rights: Results at the EU Border 2018*, Luxembourg: Publications Office of the European Commission.
- European Commission, Pan American Health Organization and World Health Organization (WHO) (2015), *Cuban Experience with Local Production of Medicines, Technology Transfer and Improving Access to Health*, Geneva: WHO.
- European Federation of Pharmaceutical Industries and Association (EFPIA) (2017), *The Pharmaceutical Industry in Figures, Key Data 2017*, available at: https://www.efpia.eu/media/219735/efpia-pharmfigures2017_statisticbroch_v04-final.pdf.
- EvaluatePharma [annual], *World Preview*, London: Evaluate.
- EvaluatePharma, *World Preview 2013, Outlook to 2018: Returning to Growth*, available at: https://info.evaluategroup.com/worldpreview2018_fp_lp.html.
- EvaluatePharma (2018a), *Orphan Drug Report 2018*, 5th Edition, London: Evaluate.
- EvaluatePharma (2018b), *World Preview 2018, Outlook to 2024*, available at: <https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-world-preview-2018-outlook-2024#download>.
- Ewen, M., Joosse, H-J, Beran, D. and Laing, R. (2019), "Insulin prices, availability and affordability in 13 low-income and middle-income countries", *BMJ Global Health* 4(3): e001410.
- Eyquem, J., Mansilla-Soto J., Giavridis, T., van der Stegen, S. J., Hamieh, M., Cunanan, K. M. et al. (2017), "Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection", *Nature* 543(7643): 113–117.
- Ferreira, R., David, F. and Nielsen, J. (2018), "Advancing biotechnology with CRISPR/Cas9: Recent applications and patent landscape", *Journal of Industrial Microbiology & Biotechnology* 45(7): 467–480.
- Fink, C. (2011), "Intellectual Property Rights", in Chauffour, J.-P. and Maur, J.-C. (eds.), *Preferential Trade Agreement Policies for Development: A Handbook*, Washington, DC: World Bank.
- Flynn, S. M., Hollis, A. and Palmedo, M. (2009), "An economic justification for open access to essential medicine patents in developing countries", *Journal of Law, Medicine and Ethics* 37(2): 184–208.
- Fojo, T., Mailankody, S. and Lo, A. (2014), "Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: The John Conley Lecture", *JAMA Otolaryngology – Head & Neck Surgery* 140(12):1225–1236.
- da Fonseca, E. M., Shadlen, K. and Bastos, F. I. (2019), "Brazil's fight against hepatitis C: Universalism, local production, and patents", *New England Journal of Medicine* 380: 605–607.
- Fontein, C., Akker, I. and Sauter, W. (2018), "Reconciling competition and IP law: the case of patented pharmaceuticals and dominance abuse", ACM Working Paper, available at: <http://eplaw.org/wp-content/uploads/2018/03/ACM-working-paper-dominance-and-patented-pharmaceuticals.pdf>.
- "Forging paths to improve diabetes care in low-income settings" (2017), editorial, *The Lancet Diabetes & Endocrinology* 5(8): 565.
- Friede, M., Palkonyay, L., Alfonso, C., Pervikov, Y. et al. (2011), "WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer", *Vaccine* 29 Supplement 1:A2-7.
- Frost, L. J. and Reich, M. R. (2010), *Access: How Do Good Health Technologies Get to Poor People in Poor Countries?*, Cambridge (MA): Harvard Center for Population and Development Studies.
- Fry, A. (2012), "Insulin Delivery Device Technology 2012: Where Are We After 90 Years?", *Journal of Diabetes Science and Technology* 6(4): 947–953.
- Gaessler, F. and Wagner, S. (2018), "Patents, Data Exclusivity and the Development of New Drugs", preliminary draft prepared for the 11th Annual Searle Centre/USPTO Conference on Innovation Economics: Work in progress, 3 June 2018.

- Gainey, L. (2018), "How the EPO treats personalised healthcare patents", *Life Sciences Intellectual Property Review*, online version, 12 October 2018.
- Gammie, T., Lu, C. Y., and Babar Z. U. (2015), "Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries", *PLoS ONE*, 9 October 2015; 10: e0140002.
- Gapper, J. (2019), "Keytruda shows the high price of curing cancer," *Financial Times*, online version, 13 February 2019, <https://www.ft.com/content/c1dacca6-2ec2-11e9-ba00-0251022932c8>.
- Garner, S., Rintoul, A. and Hill, S. R. (2018), "Value-based pricing: L'enfant terrible?", *Pharmacoeconomics* 36(1): 5–6.
- Garrido, M. V., Kristensen, F. B., Nielsen, C. P. and Busse, R. (2008), *Health Technology Assessment and Health Policy-Making in Europe: Current Status, Challenges and Potential*, Observatory Studies Series No. 14, Geneva: WHO for the European Observatory on Health Systems and Policies.
- Gaudillière, J. (2008), "How pharmaceuticals became patentable: the production and appropriation of drugs in the twentieth century", *History and Technology*, 24: 99–106.
- Gavi (2018), *Advance Market Commitment for Pneumococcal Vaccines, Annual Report 1 January – 31 December 2018*, available at: <https://www.gavi.org/investing/innovative-financing/pneumococcal-amc/>.
- Gavi (2019), *How We Work Together: Quick start guide for new members of the Vaccine Alliance*, available at: <https://www.gavi.org/library/publications/gavi/how-we-work-together/>.
- GE Healthcare (2011), "Market-relevant design: Making ECGs available across India", *The Pulse on Health, Science & Tech*, 30 September 2011.
- Geis, J. R., Brady, A., Wu, C. C., Spencer, J., Kohli, M., Ranschaert, E. et al (2019), *Ethics of AI in Radiology: European and North American Multisociety Statement*.
- Generics and Biosimilars Initiative (GaBI) (2018a), "Guidelines for biosimilars around the world", *GaBI Online*, 13 April 2018.
- Generics and Biosimilars Initiative (GaBI) (2018b), "'Similar biologics' approved and marketed in India", *GaBI Online*, 15 February 2018.
- Giannuzzi, V., Conte, R., Landi, A., Ottomano, S. A., Bonifazi, D., Baiardi, P. et al. (2017), "Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: An increased common effort is to be foreseen", *Orphanet Journal of Rare Diseases* 12(1): 64.
- Gilbert, R. (2019), "Competition, mergers and R&D diversity", *Review of Industrial Organization* 54(3): 465–484.
- Gillmore Valenzuela, I. and Santos Ossa Rogat, J., "Protección y Exclusividad de Datos de Prueba de Productos Farmacéuticos en Chile", available at: <https://revistas.uchile.cl/index.php/RDE/article/download/47370/49414/>.
- GlaxoSmithKline (2019a), "GSK announces availability of Authorized Generic Albuterol Sulfate Inhaler for treatment or prevention of bronchospasm", press release, available at: <https://us.gsk.com/en-us/products/ventolin-authorized-generic-statement/>.
- GlaxoSmithKline (2019b), "GSK grants exclusive technology license for clinical-stage Ebola vaccines to Sabin Vaccine Institute", press release, available at: <https://www.gsk.com/en-gb/media/press-releases/gsk-grants-exclusive-technology-license-for-clinical-stage-ebola-vaccines-to-sabin-vaccine-institute/>.
- Global Fund (2010), *Improving Value for Money in Global Fund-Supported Programs*, Geneva: Global Fund.
- Global Fund (2018), *Guide to Global Fund Policies on Procurement and Supply Management of Health Products*, Geneva: Global Fund.
- Goldacre, B., DeVito, N. J., Heneghan, C., Irving, F., Bacon, S., Fleming, J. et al. (2018), "Compliance with requirement to report results on the EU Clinical Trials Register: cohort study and web resource", *BMJ* 362: k3218.
- Goldman, D. P., Lakdawalla, D. N., Malkin, J. D., Romley, J. and T. Philipson (2011), "The benefits from giving makers of conventional 'small molecule' drugs longer exclusivity over clinical trial data", *Health Affairs* 30(1): 84–90.
- Gómez-Dantés, O., Wirtz, V. J., Reich, M. R., Terrazas, P. et al. (2012), "A new entity for the negotiation of public procurement prices for patented medicines in Mexico", *Bulletin of the World Health Organization* 90: 788-792, available at: <https://www.who.int/bulletin/volumes/90/10/12-106633/en/>.
- Gordon, R. J. (2018), "Why Has Economic Growth Slowed When Innovation Appears to be Accelerating?", Working Paper No. 24554, Cambridge (MA): National Bureau of Economic Research (NBER).
- Gornall, J., Hoey, A. and Ozieranski, P. (2016), "A pill too hard to swallow: how the NHS is limiting access to high priced drugs", *BMJ* 354: i4117.
- Gotham, D., Barber, M. J. and Hill, A. (2018), "Production costs and potential prices for biosimilars of human insulin and insulin analogues", *BMJ Global Health* 3(5): e000850.
- Grabowski, H. G. and Kyle, M. (2007), "Generic competition and market exclusivity periods in pharmaceuticals", *Managerial and Decision Economics* 28(4-5): 491–502.
- Greene, J. A. (2010), "When did medicines become essential?", *Bulletin of the World Health Organization* 88(7): 483.
- Griliches, Z. (1994), "Productivity, R&D, and the data constraint", *American Economic Review* 84(1): 1–23.
- Grohmann, G., Francis, D. P., Sokhey, J. and Robertson, J. (2016), "Challenges and successes for the grantees and the Technical Advisory Group of WHO's influenza vaccine technology transfer initiative", *Vaccine*, 34(45): 5420-5424.
- Gross, N. J. (2007), "Albuterol inhalers", *New England Journal of Medicine* 356(26): author reply 2749.
- Grössmann N, Del Paggio JC, Wolf S, et al. (2017), "Five years of EMA-approved systemic cancer therapies for solid tumours—a comparison of two thresholds for meaningful clinical benefit", *European Journal of Cancer* 82: 66–71.
- Guebert, J. M. and Bubela, T. (2014), "Implementing socially responsible licensing for global health: Beyond neglected diseases", *Science Translational Medicine* 6(260): 260cm11.
- Gupta, R., Shah, N. D. and Ross J. S. (2016), "The Rising Price of Naloxone—Risks to Efforts to Stem Overdose Deaths", *The New England Journal of Medicine*, 375:2213-2215, available at: <http://www.nejm.org/doi/full/10.1056/NEJMp1609578#t=article>.

- Gupta, R., Shah, N. D. and Ross J. S. (2019), "Generic Drugs in the United States: Policies to Address Pricing and Competition", *Clinical Pharmacology & Therapeutics* 105: 329–337.
- Harrer, S., Shah, P., Antony, B. and Hu, J. (2019), "Artificial Intelligence for clinical trial design", *Trends in Pharmacological Sciences* 40(8): 577–591.
- Hawkins, L. (2011), "Competition Policy", WHO/HAI Project on Medicine Prices and Availability, Review Series on Pharmaceutical Pricing Policies and Interventions, Working Paper 4, Geneva: WHO and HAI.
- Henao-Restrepo, A. M., Camacho, A., Longini, I. M., Watson, C. H., Edmunds, J., Egger, M. et al. (2017), "Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)", *The Lancet* 389(10068): 505–518.
- Herbert, M. (2018), "Enabling Innovation: SME-driven Pharmaceutical and Life Science Market Growth," UK-CPI, available at: <https://www.uk-cpi.com/blog/enabling-innovation-sme-driven-pharmaceutical-and-life-science-market-growth>.
- Herper, M. (2012), "The truly staggering cost of inventing new drugs", *Forbes*, online version, 10 February 2012.
- High-Level Panel on Access to Health Technologies (UNHLP) (2016), *Report of the United Nations Secretary-General's High-Level Panel on Access to Medicines: Promoting Innovation and Access to Health Technologies*, New York: UNHLP.
- Hill, A., Simmons, B., Gotham, D. and Fortunak, J. (2016), "Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C", *Journal of Virus Eradication* 2(1): 28–31.
- Hill, A. M., Barber, M. J. and Gotham, D. (2018), "Estimated costs of production and potential prices for the WHO Essential Medicines List", *BMJ Global Health* 3: e000571.
- HM Revenue & Customs (2016). *Policy paper. Vaccine research relief: expiry in 2017*, available at: <https://www.gov.uk/government/publications/vaccine-research-relief-expiry-in-2017/vaccine-research-relief-expiry-in-2017>.
- 't Hoen, E., Berger, J., Calmy, A., Moon, S. (2011), "Driving a decade of change: HIV/AIDS, patents and access to medicines for all", *Journal of the International AIDS Society* 14: 15.
- 't Hoen, E. F. M. (2009), *The Global Politics of Pharmaceutical Monopoly Power: Drug Patents, Access, Innovation and the Application of the WTO Doha Declaration on TRIPS and Public Health*, Diemen, The Netherlands: AMB Publishers.
- 't Hoen, E. F. M. (2014), *Access to Cancer Treatment: A Study of Medicine Pricing Issues with Recommendations for Improving Access to Cancer Medication: A Report Prepared for Oxfam*.
- 't Hoen, E. F. M., Boulet, P., Baker, B. K. (2017), "Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation", *Journal of Pharmaceutical Policy and Practice* 10:19.
- 't Hoen, E. F. M., Veraldi, J., Toebes, B. and Hogerzeil, H. V. (2018), "Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–2016", *Bulletin of the World Health Organization* 96: 185–193.
- Hogarth, S., Hopkins, M. M. and Rodriguez, V. (2012), "A molecular monopoly? HPV testing, the Pap smear and the molecularisation of cervical cancer screening in the USA", *Sociology of Health & Illness* 34(2): 234–250.
- Hogerzeil, H. V. and Mirza, Z. (2011), *The World Medicines Situation 2011: Access to Essential Medicines as Part of the Right to Health*, Geneva: WHO.
- Hogerzeil, H. V., Samson, M., Casanovas, J. V. and Rahmani-Ocora, L. (2006), "Is access to essential medicines as part of the fulfilment of the right to health enforceable through the courts?", *The Lancet* 368(9532): 305–311.
- Holloway, K. and van Dijk, L. (2011), *The World Medicines Situation 2011: Rational Use of Medicines*, Geneva: WHO.
- Holman, C. M. (2014), "Mayo, Myriad, and the future of innovation in molecular diagnostics and personalized medicine", *North Carolina Journal of Law & Technology* 15(4): 639–678.
- Hopkins, M. M. and Hogarth, S. (2012), "Biomarker patents for diagnostics: problem or solution?", *Nature Biotechnology* 30(6): 498–500.
- Hughes, D.A., Poletti-Hughes, J. (2016) "Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study", *PLoS ONE* 11(10): e0164681.
- Husereau, D. and Cameron, C. (2011), "Value-Based Pricing of Pharmaceuticals in Canada: Opportunities to Expand the Role of Health Technology", CHSRF Series of Reports on Cost Drivers and Health System Efficiency, Paper No. 5, Ottawa: Canadian Health Services Research Foundation (CHSRF).
- IFPMA (2013), *Pharmaceutical R&D Projects to Discover Cures for Patients with Neglected Conditions: 2012 Status Report on Pharmaceutical R&D to Address Diseases that Disproportionately Affect People in Low- and Middle-Income Countries*, Geneva: IFPMA, available at: https://www.ifpma.org/wp-content/uploads/2016/01/IFPMA_R_D_Status_Report_Neglected_Conditions.pdf.
- IFPMA (2017), *Doing Our Part: Innovating to Fight Neglected Tropical Diseases*, Geneva: IFPMA, available at: https://www.ifpma.org/wp-content/uploads/2017/04/IFPMA_Innovating_to_Fight_NTDs_April2017_FINAL.pdf.
- Immelt, J.R., Govindarajan, V. and Trimble, C. (2009), "How GE is disrupting itself," *Harvard Business Review*, online version, October 2009.
- Interagency Coordination Group on Antimicrobial Resistance (IACG) (2018), "Antimicrobial resistance: Invest in innovation and research, and boost R&D and access", IACG discussion paper, June 2018, available at: https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_AMR_Invest_innovation_research_boost_RD_and_access_110618.pdf?ua=1.
- Interagency Coordination Group on Antimicrobial Resistance (IACG) (2019), *No Time to Wait: Securing the Future from Drug-Resistant Infections: Report to the Secretary-General of the United Nations*.
- International Diabetes Federation (2016), *Access to Medicines and Supplies for People with Diabetes: A Global Survey on Patients' and Health Professionals' Perspective*, available at: <https://www.idf.org/component/attachments/?task=download&id=1965>.

- Ivanovska, V., Rademaker, C. M. A., van Dijk, L., Mantel-Teeuwisse, A. K. (2014), "Pediatric drug formulations: A review of challenges and progress", *Pediatrics* 134(2): 361–372.
- Iyengar, S., Tay-Teo, K., Vogler, S., Beyer, P., Wiktor, S., de Joncheere, K. et al. (2016), "Prices, costs, and affordability of new medicines for Hepatitis C in 30 countries: An economic analysis", *PLOS Medicine* 13(5): e1002032.
- Jamison, D. T., Summers, L. H., Alleyne, G., Arrow, K. J., Berkley, S., Binagwaho, A. et al. (2013), "Global health 2035: A world converging within a generation", *The Lancet* 382: 1898–1955.
- Jaspers, L., Colpani, V., Chaker, L., van der Lee, S. J., Muka, T., Imo, D. et al. (2015), "The global impact of non-communicable diseases on households and impoverishment: A systematic review", *European Journal of Epidemiology* 30(3): 163–188.
- Jayasundara, K., Hollis, A., Krahn, M., Mamdani, M., Hoch, J. S. and Grootendorst, P. (2019), "Estimating the clinical cost of drug development for orphan versus non-orphan drugs", *Orphanet Journal of Rare Diseases* 14: 12.
- Jena, A. B., Ho, O., Goldman, D. P. and Karaca-Mandic, P. (2015), "The impact of the US Food and Drug Administration chlorofluorocarbon ban on out-of-pocket costs and use of Albuterol inhalers among individuals with asthma", *JAMA Internal Medicine* 175(7): 1171–1179.
- Jenner, A., Bhagwandin, N. and Kowalski, S. (2017), *Antimicrobial Resistance (AMR) and Multidrug Resistance (MDR): Overview of Current Approaches, Consortia and Intellectual Property Issues*, Geneva: WIPO.
- Jewell, C. and Balakrishnan, V. S. (2017), "The battle to own the CRISPR–Cas9 gene-editing tool", *WIPO Magazine* 2, online version, April 2017.
- de Jongh, T., Radauer, A., Bostyn, S. and Poort, J. (2018), *Effects of Supplementary Protection Mechanisms for Pharmaceutical Products: Final Report, May 2018*, Amsterdam: Technopolis Group.
- Jürgens, B. and Clarke, N. S. (2019), "Evolution of CAR T-cell immunotherapy in terms of patenting activity", *Nature Biotechnology* 37: 370–375.
- Kahn, J. and Lauerman, J. (2018), "Google taking over health records raises patient privacy fears", *Bloomberg*, online version, 21 November 2018.
- Kaltenboeck, A. and Bach, P. B. (2018), "Value-based pricing for drugs: Theme and variations", *JAMA* 319(21): 2165–2166.
- Kampf, R. (2015), "Special Compulsory Licences for Export of Medicines: Key Features of WTO Members' Implementing Legislation", Staff Working Paper ERSD-2015-07, Geneva: WTO.
- Kaplan, W. A. and Beall, R. F. (2016), "The global intellectual property ecosystem for insulin and its public health implications: An observational study", *Journal of Pharmaceutical Policy and Practice* 10: 3.
- Kartikeyan, S., Bharmal, R. N., Tiwari, R. P. and Bisen, P. S. (2007), *HIV and AIDS: Basic elements and priorities*, Dordrecht: Springer, 2007.
- Kesselheim, A. S. (2010) "Using market-exclusivity incentives to promote pharmaceutical innovation", *New England Journal of Medicine* 363: 1855–1862.
- Kesselheim, A. S., Misono, A. S., Shrank, W. H., Greene, J. A., Doherty, M., Avorn, J. et al. (2013), "Variations in pill appearance of antiepileptic drugs and the risk of nonadherence", *JAMA Internal Medicine* 173(3): 202–208.
- Kesselheim, A. S. and Solomon, D. H. (2010), "Incentives for drug development—the curious case of colchicine", *New England Journal of Medicine* 362: 2045–2047.
- Khor, M. (2007), "Patents, Compulsory Licences and Access to Medicines: Some Recent Experiences", TWN Intellectual Property Series 10, Penang, Malaysia: Third World Network (TWN).
- Kim, C. and Prasad, V. (2015), "Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: An analysis of 5 years of US Food and Drug Administration approvals", *JAMA Internal Medicine* 359: 1992–1994.
- King, D. R. and Kanavos, P. (2002), "Encouraging the use of generic medicines: Implications for transition economies", *Croatian Medical Journal* 43(4): 462–69.
- Kittittrakul, C. (2018a), presentation at the Academic Forum on Lessons Learned of Drug Patents' Opposition and Withdrawal in Thailand, held at the Faculty of Pharmaceutical Science, Chulalongkorn University, 18 May 2018.
- Kittittrakul, C. (2018b), presentation at the Civil Society Organizations' Meeting on Hepatitis C: Emerging Evidences and Scaling-up Response, Bangkok, 6–7 June 2018.
- Kmietowicz, Z. (2015a), "Campaigners demand right to generic version of breast cancer drug", *BMJ* 351: h5279.
- Kmietowicz, Z. (2015b), "China rejects patent on hepatitis C drug sofosbuvir", *BMJ* 350: h3429.
- Kneller, R. (2010), "The importance of new companies for drug discovery: Origins of a decade of new drugs", *Nature Reviews Drug Discovery* 9: 867–882.
- Kohli, M. and Geis, R. (2018), "Ethics, Artificial Intelligence, and Radiology", *Journal of the American College of Radiology* 15(9): 1317–1319.
- Kolata, G. (1991), "Patients Going Underground to Buy Experimental Drugs", *New York Times*, Section A, p. 1, available at: <https://www.nytimes.com/1991/11/04/us/patients-going-underground-to-buy-experimental-drugs.html?searchResultPosition=22>.
- de Kraker, M.E.A., Stewardson, A.J. and Harbarth, S. (2016), "Will 10 million people die a year due to antimicrobial resistance by 2050?", *PLoS Medicine* 13(11): e1002184.
- Krasovec, K. and Connor, C. (1998), *Using Tax Relief to Support Public Health Goals*, Partners for Health Reformplus.
- Krattiger, A. (2007a), "Freedom to Operate, Public Sector Research, and Product-Development Partnerships, Strategies, and Risk-Management Options", in Krattiger, A. et al. (eds.), *Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices*, Oxford and Davis (CA): Centre for the Management of Intellectual Property in Health Research and Development (MIHR) and Public Intellectual Property Resource for Agriculture (PIPRA): 1317–1327.
- Krattiger, A. (2007b), "The Use of Nonassertion Covenants: A Tool to Facilitate Humanitarian Licensing, Manage Liability, and Foster Global Access", in Krattiger, A. et al. (eds.), *Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices*, Oxford and Davis (CA): Centre for

the Management of Intellectual Property in Health Research and Development (MIHR) and Public Intellectual Property Resource for Agriculture (PIPRA): 739–745.

Krattiger, A., Bombelles, T., Bartels, H. G., Mirza, Z., Beyer, P. Taubman, A. et al. (2015), "Promoting Medical Innovation and Access Together: Trilateral Cooperation between WHO, WIPO and WTO", Global Challenges Brief on Trilateral Cooperation, Geneva: WIPO.

Kulkarni, P.S., Socquet, M., Jadhav, S.S., Kapre, S.V., LaForce, F.M. and Poonawalla, C.S. (2015), "Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective from the Serum Institute of India", *Clinical Infectious Diseases* 61: S483–S488.

Kwon, D. (2019), "A brief guide to the current CRISPR landscape", *The Scientist*, online version, 15 July 2019.

Kyle, M. and Qian, Y. (2014), "Intellectual Property Rights and Access to Innovation: Evidence from TRIPS", Working Paper No. 20799, Cambridge (MA): National Bureau of Economic Research (NBER).

LaMattina, J. L. (2011), "The impact of mergers on pharmaceutical R&D", *Nature Reviews. Drug Discovery* 10: 559–560.

LaMattina, J. L. (2015), "FDA approvals 1996 vs. 2014: The two most prolific years, but stark differences", *Forbes*, online version, 7 January 2015.

Lander, E., Baylis, F., Zhang, F., Charpentier, E., Berg, P. et al. (2019), "Adopt a moratorium on heritable genome editing", *Nature*, online version, 13 March 2019.

Langreth, R. (2019), "Alzheimer's Drug Failure Leaves Scientists Seeking New Direction", *Bloomberg*, online version, 22 March 2019, available at: <https://www.bloomberg.com/news/articles/2019-03-22/alzheimer-s-drug-fails-and-scientists-ask-is-it-time-to-move-on>.

Lanjouw, J. O. (2005), "Patents, Price Control, and Access to New Drugs: How Policy Affects Global Market Entry", Working Paper No. 11321, Cambridge (MA): National Bureau of Economic Research (NBER).

Laustsen, A. H., Johansen, K. H., Engmark, M. and Andersen, M. R. (2017), "Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?" *PLoS Neglected Tropical Diseases* 11(2): e0005361.

Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J.-A., Klugman, K. et al. (2016), "Access to effective antimicrobials: A worldwide challenge", *The Lancet* 387(10014):168–175.

Lesser, N. and Hefner, M. (2017), "R&D partnerships – Partnering for progress: How collaborations are fuelling biomedical advances", *Drug Development*, online version, November–December 2017.

Leucht, S., Helfer, B., Gartlehner, G. and Davis, J. M. (2015), "How effective are common medications: A perspective based on meta-analyses of major drugs", *BMC Medicine* 13: 253.

Levin, R. C., Klevorick, A. K., Nelson, R. R. and Winter, S. G. (1987), "Appropriating the Returns from Industrial Research and Development", *Brookings Papers on Economic Activity* 3: 783–831.

Lexchin, J. (2012), "International comparison of assessments of pharmaceutical innovation", *Health Policy* 105(2–3): 221–225.

Lichtenberg, F. (2012), "Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-Income Countries, 2000–2009", Working Paper No. 18235, Cambridge (MA): National Bureau of Economic Research (NBER).

Lloyd, M. (2013), "Evergreening by whom? A review of secondary patents for omeprazole", *Pharmaceutical Patent Analyst* 2(6), available at <http://www.future-science.com/doi/abs/10.4155/ppa.13.57>.

Lock, H. (2019), "Fight the fakes: how to beat the \$200bn medicine counterfeiters", *The Guardian*, 5 June 2019.

Long, G. (2017), *The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development*, Boston (MA): Analysis Group.

Love, J. (2003), "Evidence Regarding Research and Development Investments in Innovative and Non-Innovative Medicines", Washington, DC: Consumer Project on Technology.

Lunze, A. (2019), "No compulsory licence for Sanofi's Praluent in Germany", available at: <https://united-kingdom.taylorwessing.com/synapse/ti-sanofi-licence.html>.

Luo, J. and Kesselheim, A. S. (2015) "Evolution of insulin patents and market exclusivities in the USA", *The Lancet Diabetes & Endocrinology* 3(11): 835–837.

Mackey, T. K. and Liang, B. A. (2012), "Patent and exclusivity status of essential medicines for non-communicable disease", *PLoS ONE* 7(11): e51022.

Madian, A. G., Wheeler, H. E., Jones, R. B. and Dolan, M. E. (2012), "Relating human genetic variation to variation in drug responses", *Trends in Genetics* 28(10): 487–495.

Magrini, N., Robertson, J., Forte, G., Cappello, B., Moja, L. P., de Joncheere, K. et al. (2015), "Tough decisions on essential medicines in 2015", *Bulletin of the World Health Organization* 93: 283–284.

Maistat, L., Kravchenko, N. and Reddy, A. (2017), "Hepatitis C in Eastern Europe and Central Asia: a survey of epidemiology, treatment access and civil society activity in eleven countries", *Hepatology, Medicine and Policy* 2:9. DOI: 10.1186/s41124-017-0026-z.

Makin, S. (2018), "The amyloid hypothesis on trial", *Nature*; 559: S4–7.

Malerba, F. and Orsenigo, L. (2015), "The evolution of the pharmaceutical industry", *Business History* 57(5): 664–687.

Management Sciences for Health (MSH) (2012), *MDS-3: Managing Access to Medicines and Health Technologies*, Arlington (VA): MSH.

Mandel, G. N. (2006), "The generic biologics debate: Industry's unintended admission that biotech patents fail enablement", *Virginia Journal of Law & Technology* 11(8).

Maniadakis, N., Holtorf, A.-P., Otávio Corrêa, J. O., Gialama, F. and Wijaya, K. (2018), *Applied Health Economics and Health Policy* 16(5): 591–607.

Mansfield, E. (1986), "Patents and innovation: An empirical study", *Management Science* 32(2): 173–181.

Marks, L. V. (2015), *The Lock and Key of Medicine: Monoclonal Antibodies and the Transformation of Healthcare*. New Haven: Yale University Press.

Marshall, A. D., Cunningham, E. B., Nielsen, S., Aghemo, A., et al. (2018), "Restrictions for reimbursement of interferon-free

- direct-acting antiviral drugs for HCV infection in Europe”, *The Lancet Gastroenterology & Hepatology* 3(2): 125–133.
- Martin-Laffon, J., Kuntz, M. and Ricroch, A. E. (2019), “Worldwide CRISPR patent landscape shows strong geographical biases”, *Nature Biotechnology* 37: 613–620.
- Martinez, C. (2010), “Insight into Different Types of Patent Families”, OECD Science, Technology and Industry Working Papers No. 2010/02, Paris: OECD Publishing.
- Masini, T., Hauser, J., Kuwana, R., Nhat Linh, N. and Jaramillo, E. (2018), “Will regulatory issues continue to be a major barrier to access to bedaquiline and delamanid?” *European Respiratory Journal* 51(3): 1702480.
- Masum, H. and Harris, R. (2011), *Open Source for Neglected Disease: Magic Bullet or Mirage?*, Washington, DC: Results for Development Institute.
- Matthijs, G. and van Ommen, G.-J. B. (2009), “Gene Patents: From Discovery to Invention. A Geneticist’s View”, in Van Overwalle, G. (ed.), *Gene Patents and Collaborative Licensing Models: Patent Pools, Clearinghouses, Open Source Models and Liability Regimes*, Cambridge (UK): Cambridge University Press.
- Maurer, S. (2007), “Open source drug discovery: Finding a niche (or maybe several)”, *UMKC Law Review* 76(2): 405–435.
- McConaghie, A. (2019), “Orkambi row: government now considering Crown Use licensing”, *PMLive*, 20 June 2019, available at: http://www.pmlive.com/pharma_news/orkambi_row_government_says_now_considering_crown_licensing_1290525.
- McDonald, S. A., Mohamed, R., Dahlui, M., Naning, H., et al. (2014), “Bridging the data gaps in the epidemiology of hepatitis C virus infection in Malaysia using multi-parameter evidence synthesis”, *BMC Infectious Diseases* 14(564). DOI: 10.1186/s12879-014-0564-6.
- Médecins Sans Frontières (MSF) (2016), “MSF launches challenge to Pfizer’s patent on the pneumonia vaccine in India to increase access to more affordable versions”, available at: <https://www.msf.org/access-msf-launches-challenge-pfizers-patent-pneumonia-vaccine-india-increase-access-more>.
- Médecins Sans Frontières (MSF) (2018), “A fair shot for affordable pneumonia vaccine: Why overcoming patent barriers to PCV13 is vital for saving children’s lives?”, *Rinsho Hyoka=Clinical Evaluation* 46(2): W45–W48, available at: http://cont.o.oo7.jp/46_2/w45-w48.pdf.
- Megget, K. (2018), “Novartis exit from antibiotics a setback for race against resistance”, *Chemistry World*, available at: <https://www.chemistryworld.com/news/novartis-exit-from-antibiotics-a-setback-for-race-against-resistance/3009316.article>.
- Merges, R. P. and Mattioli, M. (2017), “Measuring the costs and benefits of patent pools”, *Ohio State Law Journal* 78(2): 281–347.
- Miller, J. (2018), “Novartis’s pricing might be tested with costly eye therapy,” Reuters, online version, 23 November 2018, available at: <https://www.reuters.com/article/us-novartis-luxturna/novartiss-pricing-might-be-tested-with-costly-eye-therapy-idUSKCN1NS0FM>.
- Miller, K. L. and Lanthier, M. (2018), “Investigating the landscape of US orphan product approvals”, *Orphanet Journal of Rare Diseases* 13: 183.
- Miller, S. and Hicks G. N. (2015), “Investor-State Dispute Settlement: A Reality Check”, Center for Strategic and International Studies, available at: https://csis-prod.s3.amazonaws.com/s3fs-public/legacy_files/files/publication/150116_Miller_InvestorStateDispute_Web.pdf.
- Mirza, Z. (2008), “Thirty years of essential medicines in primary health care”, *Eastern Mediterranean Health Journal* 14 (Supp.): S74–S81.
- Mohara, A., Yamabhai, I., Chaisiri, K., Tantivess, S. and Teerawattananon, Y. (2012), “Impact of the introduction of government use licenses on the drug expenditure on seven medicines in Thailand”, *Value in Health* 15(1 Supp.): S95–S99.
- Mok, K. (2018), “IBM combines AI and blockchain to identify counterfeits”, *The New Stack*, 22 June 2018.
- Mongan, A.-M. (2018), “Tech Giants Tackle Health Care: An Opportunity or Threat for the Pharmaceutical Industry”, *Clinical Trials Arena*, online version, 7 August 2018, available at: <https://www.clinicaltrialsarena.com/comment/tech-giants-tackle-health-care-opportunity-threat-pharmaceutical-industry/>.
- Moon, S. (2011), *Pharmaceutical Production and Related Technology Transfer*, Geneva: WHO.
- Moon, S. and Erickson, E. (2019), “Universal medicine access through lump-sum remuneration—Australia’s approach to Hepatitis C”, *New England Journal of Medicine* 380: 607–610.
- Moran, M., Ropars, A.-L., Guzman, J., Diaz, J. and Garrison, C. (2005), *The New Landscape of Neglected Disease Drug Development*, London: The Wellcome Trust.
- Morgan, S., Grootendorst, P., Lexchin, J., Cunningham, C. and Greyson, D. (2011), “The cost of drug development: A systematic review”, *Health Policy* 100(1): 4–17.
- Mowery, D. C. and Sampat, B. N. (2001a), “Patenting and licensing university inventions: lessons from the history of the research corporation”, *Industrial and Corporate Change*, 10.2: 317–355.
- Mowery, D. C. and Sampat, B. N. (2001b), “University patents and patent policy debates in the USA, 1925–1980”, *Industrial and Corporate Change*, 10.3: 781–814.
- MRC Laboratory of Molecular Biology (1984), 1984 Physiology or Medicine Prize – César Milstein & Georges Köhler, available at: <http://www2.mrc-lmb.cam.ac.uk/achievements/lmb-nobel-prizes/1984-cesar-milstein-georges-kohler/>.
- MSF Access Campaign (2015), *The Right Shot: Bringing Down Barriers to Affordable and Adapted Vaccines*, 2nd Edition, Geneva: Médecins Sans Frontières.
- MSF Access Campaign (2017), *A Fair Shot for Vaccine Affordability: Understanding and Addressing the Effects of Patents on Access to Newer Vaccines*, Geneva: Médecins Sans Frontières.
- Mulcahy, A. W., Predmore, Z. and Mattke, S. (2014), *The Cost Savings Potential of Biosimilar Drugs in the United States*, Santa Monica (CA): RAND Corporation.
- Mullard, A. (2019), “Anti-amyloid failures stack up as Alzheimer antibody flops”, *Nature Reviews Drug Discovery*, online version, 5 April 2019.
- Mullin, E. (2017), “CRISPR in 2018: Coming to a human near you”, *MIT Technology Review*, online version, 18 December 2017.

- Murray, C. J. L. and Lopez, A. D. (eds.) (1996), *The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020*, Boston (MA): Harvard School of Public Health.
- National Institutes of Health (NIH) (2001), *Glossary of Terms for Human Subjects Protection and Inclusion Issues*, Washington, DC: NIH.
- National Research Council (2003), *Patents in the Knowledge-Based Economy*. Washington, DC: The National Academies Press, available at: <https://doi.org/10.17226/10770>.
- National Research Council (2011), *Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease*. Washington, DC: The National Academies Press, available at: <https://doi.org/10.17226/13284>.
- NCD Alliance (2011), "Access to Essential Medicines and Technologies for NCDs", Briefing Paper, Geneva: NCD Alliance.
- Newsome, C. (2017), "Basaglar", *Clinical Diabetes* 35(3): 181.
- Nguyen, T-Y, Veras, J and Shahzad, M. (2018), "Recent Experiences in Policy Implementation of Socially Responsible Licensing in Select Universities Across Europe and North America: Identifying Key Provisions to Promote Global Access to Health Technologies", *Les Nouvelles: The Journal of the Licensing Executives Society International* LIII(3).
- Niëns, L., Cameron, A., Van de Poel, E., Ewen, M., Brouwer, W. B. and Laing, R. (2010), "Quantifying the impoverishing effects of purchasing medicines: A cross-country comparison of the affordability of medicines in the developing world", *PLoS Medicine* 7(8): e1000333.
- Niraula, S., Seruga, B., Ocana, A., Shao, T., Goldstein, R., Tannock, I. F. et al. (2012), "The price we pay for progress: A meta-analysis of harms of newly approved anticancer drugs", *Journal of Clinical Oncology* 30(24): 3012–3019.
- Nunn, A. S., Fonseca, E. M., Bastos, F. I., Gruskin, S. and Salomon, J. A. (2007), "Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment", *PLoS Medicine* 4(11): e305.
- Obrist, B., Iteba, N., Lengeler, C., Makemba, A., Mshana, C., Nathan, R. et al. (2007), "Access to health care in contexts of livelihood insecurity: A framework for analysis and action", *PLoS Medicine* 4(10): e308.
- Office of the United Nations High Commissioner for Human Rights (OHCHR) and World Health Organization (WHO) (2008), "The Right to Health", Fact Sheet No. 31, Geneva: OHCHR and WHO.
- Olcay, M. and Laing, R. (2005), "Pharmaceutical Tariffs: What is Their Effect on Prices, Protection of Local Industry and Revenue Generation?: Prepared for: The Commission on Intellectual Property Rights, Innovation and Public Health", Geneva: WHO.
- Olliaro, P. L., Kuesel, A. C., Halleux, C. M., Sullivan, M. and Reeder, J. C. (2018), "Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years", *PLoS Neglected Tropical Diseases* 12(11): e0006837.
- Olson, L. M. and Wendling, B. W. (2013), "The Effect of Generic Drug Competition on Generic Drug Prices during the Hatch-Waxman 180-day Exclusivity Period", Working Paper No. 317, FTC Bureau of Economics, Washington, DC.
- Olson, S. and Berger, A. (2011), *Establishing Precompetitive Collaborations to Stimulate Genomics-Driven Drug Development: Workshop Summary*, Washington, DC: National Academies Press.
- O'Neill, J. (2016), The Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations, available at: [https://amr-review.org/sites/default/files/160525_Final paper_with cover.pdf](https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf).
- Organisation for Economic Co-operation and Development (OECD) (2008), *Pharmaceutical Pricing Policies in a Global Market*, Paris: OECD.
- Organisation for Economic Co-operation and Development (OECD) (2017a), *Health at a Glance 2017: OECD Indicators*, Paris: OECD.
- Organisation for Economic Co-operation and Development (OECD) (2017b), Tackling Wasteful Spending on Health, available at: <https://www.oecd.org/els/health-systems/Tackling-Wasteful-Spending-on-Health-Highlights-revised.pdf>.
- Organisation for Economic Co-operation and Development (OECD) (2018), "Pharmaceutical Innovation and Access to Medicines", *OECD Health Policy Studies*, p. 143, available at: <http://www.oecd.org/health/pharmaceutical-innovation-and-access-to-medicines-9789264307391-en.htm>.
- Organisation for Economic Co-operation and Development (OECD) and European Union Intellectual Property Office (EUIPO) (2019), *Trends in Trade in Counterfeit and Pirated Goods*, Paris: OECD Publishing.
- Organisation of Eastern Caribbean States (OECS) (2001), *Pharmaceutical Procurement Service Annual Report 2001*, Saint Lucia: OECS.
- Pagliusi, S., Dennehy, M. and Kim, H. (2018), "Vaccines, inspiring innovation in health", *Vaccine* 36: 7430–7437.
- Pammolli, F., Magazzini, L. and Riccaboni, M. (2011), "The productivity crisis in pharmaceutical R&D", *Nature Reviews Drug Discovery* 10(6): 428–438.
- Paris, V. and Belloni, A. (2013), "Value in Pharmaceutical Pricing", Health Working Papers No. 63, Paris: OECD.
- Parsons, L. (2019), "Vertex, NHS England and NICE finally reach agreement for Orkambi", *PMLive*, 24 October 2019, available at: http://www.pmlive.com/pharma_news/vertex_nhs_england_and_nice_finally_reach_agreement_for_orkambi_1314406?utm_source=pmlive&utm_medium=email&utm_campaign=pmlive_daily&
- Paun, C. (2016), "Skyhigh drug prices made Romania mull patent break", *Politico*, online version, 29 March 2016.
- Penazzato, M., Lewis, L., Watkins, M., Prabhu, V., Pascual, F., Auton, M. et al. (2018), "Shortening the decade-long gap between adult and paediatric drug formulations: A new framework based on the HIV experience in low- and middle-income countries", *Journal of the International AIDS Society* 21(Suppl.1): e25049.
- Perehudoff, S. K., Toebes, B. and Hogerzeil, H. (2016), "Essential medicines in national constitutions: Progress since 2008", *Health and Human Rights Journal* 18(1): 141–156.
- Pettitt, D., Arshad, Z., Smith, J., Stanic, T., Holländer, G. and Brindley, D. (2018), "CAR-T cells: A systematic review and mixed-methods analysis of the clinical trial landscape", *Molecular Therapy* 26(2): 342–353.

- von Philipsborn, P., Steinbeis, F., Bender, M. E., Regmi, S. and Tinnemann, P. (2015), "Poverty-related and neglected diseases: An economic and epidemiological analysis of poverty relatedness and neglect in research and development", *Global Health Action* 8(1), online version, 22 January 2015.
- PhRMA, PhRMA Annual Membership Survey 2018, available at: <https://heatinformatics.com/posts/2018-phrma-annual-membership-survey>.
- Prasad, V. and Mailankody, S. (2017), "Research and development spending to bring a single cancer drug to market and revenues after approval", *JAMA Internal Medicine* 177(11): 1569–1575.
- Pray, L. (2008), "Personalized medicine: Hope or hype?," *Nature Education* 1(1):72.
- Price, W. N. and Rai, A. K. (2015), "Are trade secrets delaying biosimilars?," *Science* 348(6231): 188–189.
- Price, W. N. and Rai, A. K. (2016), "Manufacturing barriers to biologics competition and innovation", *Iowa Law Review* 101(3): 1023–1063.
- Pricewaterhousecoopers International Ltd (PwC) (2008), *Pharma 2020: Virtual R&D – Which Path Will You Take?*, PwC.
- Pulcini, C., Mohrs, S., Beovic, B., Gyssens, I., Theuretzbacher, U. and Cars, O. (2016), "Forgotten antibiotics: A follow-up inventory study in Europe, the USA, Canada and Australia", *International Journal of Antimicrobial Agents* 49(1): 98–101.
- Quinn, R. (2013), "Rethinking antibiotic research and development: World War II and the penicillin collaborative", *American Journal of Public Health* 103(3): 426–434.
- Quintilio, W., Kubrusly, F.S., Iourtov, D., Miyaki, C., Sakauchi, M.A., et al. (2009), "*Bordetella pertussis* monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice", *Vaccine* 27(31): 4219–4224.
- Rägo, L. and Santoso, B. (2008), "Drug Regulation: History, Present and Future", in van Boxtel, C. J., Santoso, B. and Edwards, I. R. (eds.), *Drug Benefits and Risks: International Textbook of Clinical Pharmacology*, 2nd Edition, Amsterdam: IOS Press.
- Rao, A. (2011), "New technologies for neglected diseases: Can tax credits help biotechnology companies advance global health?" *Journal of Commercial Biotechnology* 17: 290–292, available at: <https://paperity.org/p/76961659/new-technologies-for-neglected-diseases-can-tax-credits-help-biotechnology-companies>.
- Reardon, S. (2014), "Ebola treatments caught in limbo", *Nature* 511(7511): 520.
- Reátegui Valdiviezo, M. (2016), "Datos de Prueba de Productos Farmacéuticos. Análisis de la Legislación Peruana y Tratados Aplicables", *Revista Derecho & Sociedad* 49: 143–159, available at: <http://revistas.pucp.edu.pe/index.php/derechosociedad/article/download/19884/19923>.
- Reich, M. R., Harris, J., Ikegami, N., Maeda, A., Cashin, C., Araujo, E. C., et al. (2016), "Moving towards universal health coverage: Lessons from 11 country studies", *The Lancet* 387(10020): 811–816.
- Relias Media (2005), "FDA drug approvals jump in 2004", online version, 1 May 2005, available at: <https://www.reliasmedia.com/articles/87040-fda-drug-approvals-jump-in-2004>.
- Renwick, M.J., Simpkin V, Mossialos, E. (2016), *International and European Initiatives Targeting Innovation in Antibiotic Drug Discovery and Development, The Need for a One Health – One Europe – One World Framework*, Health Policy Series 45.
- Reuters (2016), "Beijing buyers club? China's cancer patients gamble on gray market", *Business Insider*, online version, 25 December 2016, available at: <http://static3.businessinsider.com/r-beijing-buyers-club-chinas-cancer-patients-gamble-on-gray-market-2016-12>.
- Reuters (2018), "Impatient patients turn to online 'buyers club' for new drugs", *CNBC*, online version, 3 October 2018, available at: <https://www.cnbc.com/2018/10/03/impatient-patients-turn-to-online-buyers-club-for-new-drugs.html>.
- Ridley, D. B. and Régnier, S. A. (2016), "The commercial market for priority review vouchers", *Health Affairs* 35(5): 776–783.
- Rietveld, H. (2008), "A New Class of Malaria Drugs: The Coartem Breakthrough from Novartis and its Chinese Partners", PowerPoint presentation to Workshop on Access and Benefit Sharing, Bonn, 26 May 2008.
- Robertson, J., Forte, G., Trapsida, J.-M. and Hill, S. (2009), "What essential medicines for children are on the shelf?," *Bulletin of the World Health Organization* 87(3): 231–237.
- Rodríguez, P.C., Rodríguez, G., González, G. and Lage, A. (2010), "Clinical Development and Perspectives of CIMAvax EGF, Cuban Vaccine for Non-small-cell Lung Cancer Therapy", *MEDICC Review* 12(1): 17–23.
- Roger, S. D. and Goldsmith, D. (2008), "Biosimilars: It's not as simple as cost alone", *Journal of Clinical Pharmacy and Therapeutics* 33(5): 459–464.
- Rosenfeld, L. (2002), "Insulin: discovery and controversy", *Clinical Chemistry* 48(12): 2270–2288.
- Roth, V. J. (2012), "Will FDA data exclusivity make biologic patents passé?," *Santa Clara High Technology Law Journal* 29(2): 249–304.
- Röttingen, J.-A., Chamas, C., Goyal, L. C., Harb, H., Lagrada, L. and Mayosi, B. M. (2012), "Securing the public good of health research and development for developing countries", *Bulletin of the World Health Organization* 90(5): 398–400.
- Roughead, E. E., Kim, D. S., Ong, B. and Kemp-Casey, A. (2018), "Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price", *WHO South-East Asia Journal of Public Health*, September 2018 7(2): 99–106.
- Roughead, L., Semple, S. and Rosenfeld, E. (2013), *Literature Review: Medication Safety in Australia*, Darlinghurst (NSW): Australian Commission on Quality and Safety in Health Care.
- Russian Federation, Ministry of Health and World Health Organization (WHO) (2017), *Moscow Declaration to End TB*, First WHO Global Ministerial Conference: Ending TB in the Sustainable Development Era: A Multisectoral Response, 16–17 November 2017, Moscow, Russian Federation.
- Sag, M. (2009), "Copyright and copy-reliant technology", *Northwestern University Law Review* 103(4): 1607–1682.
- Sagonowsky, E. (2017), "Promising Ebola vaccines from Merck, Johnson & Johnson win BARDA funding", *FiercePharma*, online version, 2 October 2017, available at: <https://www.fiercepharma.com/vaccines/promising-ebola-vaccines-from-merck-j-j-win-barda-funding>.

- Sagonowsky, E. (2018), "Merck Starts Rolling FDA Submission for Its Ebola Vaccine, Aiming to Finish Next Year", *Fiercepharma*, online version, 15 November 2018, available at: <https://www.fiercepharma.com/vaccines/merck-starts-fda-submission-for-ebola-vaccine-aiming-to-finish-next-year>.
- El Said, M. K. (2010), *Public Health Related Trips-Plus Provisions in Bilateral Trade Agreements: A Policy Guide for Negotiators and Implementers in the WHO Eastern Mediterranean Region*, Geneva: WHO and ICTSD.
- Sampat, B. N. (2015), "Intellectual Property Rights and Pharmaceuticals: The Case of Antibiotics", Economic Research Working Paper No. 26, Geneva: WIPO.
- Sampat, B. N. and Shadlen, K. (2016), The Effects of Restrictions on Secondary Pharmaceutical Patents: Brazil and India in Comparative Perspective, available at: <http://www.hbs.edu/faculty/Lists/Events/Attachments/1124/Secondary%20Pharma.pdf>.
- Sanchez-Luna, M., Burgos-Pol, R., Oyagüez, I., Figueras-Aloy, J., Sánchez-Solis, M., Martínón-Torres, F. et al. (2017), "Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: Update based on the clinical evidence in Spain", *BMC Infectious Diseases* 17(1): 687.
- Sarbacker, G. B. and Urteaga, E. M. (2016), "Adherence to Insulin Therapy", *Diabetes Spectrum* 29(3): 166–170.
- Savedoff, W. D. (2011), "Governance in the Health Sector: A Strategy for Measuring Determinants and Performance", Policy Research Working Paper No. 5655, Washington, DC: World Bank.
- Scaria, A. G. and Mammen, K. S. (2018), "Non-Traditional Marks in the Pharmaceutical Sector: Non-Traditional Barriers to Access to Medicine?" in Calboli, I. and Sentleben, M. (eds.), *The Protection of Non-Traditional Trademarks: Critical Perspectives*, Oxford: Oxford University Press.
- Schafer, J., Tapella, M., Kantarelis, T. (2016), "Biosimilars: Why deep discounts may become the dominant paradigm", *Pharmaceutical Commerce*, online version, 22 February 2016.
- Schell, J. (2013), "Neurim: a new definition of 'product' in supplementary protection certificates?", *Journal of Intellectual Property Law & Practice* 8(9): 723–728, available at: <https://doi.org/10.1093/jiplp/jpt130>.
- Scherer, F. M. and Watal, J. (2002), "Post-TRIPS options for access to patented medicines in developing nations", *Journal of International Economic Law* 5(4): 913–939.
- Schmucker, C., Schell, L. K., Portalupi, S., Oeller, P., Cabrera, L., Bassler, D. et al. (2014), "Extent of non-publication in cohorts of studies approved by research ethics committees or included in trial registries", *PLoS ONE* 9: e114023.
- Schuhmacher, A., Gassman, O. and Hinder, M. (2016), "Changing R&D models in research-based pharmaceutical companies", *Journal of Translational Medicine*, 14(1): 105.
- Schuhmacher, A., Gassman, O., McCracken, N. and Hinder, M. (2018), "Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?", *Journal of Translational Medicine* 16:119.
- Schwieterman, W. D. (2006), "Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective", *Drug Discovery Today* 11(19–20): 945–951.
- Scutti, S. (2018), "Gene therapy for rare retinal disorder to cost \$425,000 per eye", *CNN*, online version, 3 January 2018, available at: <https://www.cnn.com/2018/01/03/health/luxturna-price-blindness-drug-bn/index.html>.
- Shapiro, C. (2001), "Navigating the Patent Thicket: Cross Licences, Patent Pools and Standard Setting", in Jaffe, A. B., Lerner, J. and Stern, S. (eds.), *Innovation Policy and the Economy*, vol. 1, Cambridge (MA): MIT Press.
- Shcherbakova, N., Shepherd, M., Lawson, K. and Richards, K. (2011), "The role of authorized generics in the prescription drug marketplace", *Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector* 8: 28–40.
- Shedden, K. (2018), presentation at Sustainable Development Goals: Innovative Technologies to Promote Healthy Lives and Well-being, A Joint Technical Symposium by the WHO, WIPO and WTO, Geneva, 26 February 2018.
- Shum, T., Kruse, R. L. and Rooney, C. M. (2018), "Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities", *Expert Opinion on Biological Therapy* 18(6): 653–664.
- Silverman, E. (2017a), "Netherlands health minister threatens compulsory licenses over 'absurd prices'", *STAT News*, available at: <https://www.statnews.com/pharmalot/2017/11/27/netherlands-patents-compulsory-licenses-vertex/>.
- Silverman, E. (2017b), "Under pressure, Gilead expands Sovaldi licensing deal to four middle-income countries", *STAT News*, available at: <https://www.statnews.com/pharmalot/2017/08/24/gilead-sovaldi-malaysia-ukraine/>.
- Simon-Kucher & Partners (2016), *Payers' Price & Market Access Policies Supporting a Sustainable Biosimilar Medicines Market: Final Report*, Bonn: Simon-Kucher & Partners.
- Son, K., Lopert, R., Gleeson, D. and Lee, T. (2018), "Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States", *Globalization and Health* 14(101), available at: <https://doi.org/10.1186/s12992-018-0423-0>.
- Srivastava, R. K. and More, A. T. (2010), "Some aesthetic considerations for over the-counter (OTC) pharmaceutical products", *International Journal of Biotechnology* 11(3-4): 267–283.
- Stanaway, J. D., Afshin, A., Gakidou, E., Lim, S. S., Abate, D., Abate, K. H., et al. (2018), "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017", *The Lancet* 392(10159): 1923–1994.
- Stenberg, K., Hanssen, O., Edejer, T. T., Bertram, M., Brindley, C., Meshrek, A. et al. (2017), "Financing transformative health systems towards achievement of the health Sustainable Development Goals: A model for projected resource needs in 67 low-income and middle-income countries", *The Lancet Global Health* 5(9): e875–e887.
- Stevens, A. J. and Effort, A. E. (2008), "Using academic license agreements to promote global social responsibility", *Les Nouvelles* 43: 85.
- Stevens, A. J., Jensen, J. J., Wyller, K., Kilgore, P. C., Chatterjee, S. and Rohrbach, M. L. (2011), "The role of public-sector

- research in the discovery of drugs and vaccines”, *New England Journal of Medicine* 364(6): 535–541.
- Sussex, J., Feng, Y., Mestre-Ferrandiz, J., et al. (2016), “Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom”, *BMC Medicine* 14(32), online version, 25 February 2016.
- Tängdén, T., Pulcini, C., Aagaard, H., Balasegaram, M., et al. (2018), “Unavailability of old antibiotics threatens effective treatment for common bacterial infections”, *The Lancet Infectious Diseases* 18(3): 242–244.
- Tay-Teo, K., Ilbawi, A. and Hill, S. R. (2019), “Comparison of sales income and research and development costs for FDA-approved cancer drugs sold by originator drug companies”, *JAMA Network Open* 2(1): e186875.
- Taylor, C. T. and Silberston, Z. A. (1973), *The Economic Impact of the Patent System: A Study of the British Experience*, Cambridge: Cambridge University Press.
- Temin, P. (1979), “Technology, regulation, and market structure in the modern pharmaceutical industry”, *The Bell Journal of Economics* 10(2): 429–446.
- Tenn, S. & Wendling, B. W. (2014), “Entry threats and pricing in the generic drug industry”, *Review of Economics and Statistics* 96: 214–228.
- Thomas, J. R. (2014), *The Role of Patents and Regulatory Exclusivities in Pharmaceutical Innovation*, Washington, DC: Congressional Research Service.
- Thomas, J. R. (2015), *Pharmaceutical Patent Law*, 3rd Edition, Arlington (VA): Bloomberg BNA.
- Todd, Matthew (2010), “A Summary of What Is Needed Right Now”, The Synaptic Leap’s Synthetic Praziquantel Project, available at: <http://www.thesynapticleap.org/node/286>.
- Toebes, B., Ferguson, R., Markovic, M. M. and Nnamuchi, O. (eds.) (2014), *The Right to Health, A Multi-Country Study of Law, Policy and Practice*, Den Haag: Asser Press.
- Toland, A. E., Forman, A., Couch, F. J., Culver, J. O., et al. on behalf of the BIC Steering Committee (2018), “Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices”, *npj Genomic Medicine* 3(7), available at: [10.1038/s41525-018-0046-7](https://doi.org/10.1038/s41525-018-0046-7).
- Tomas Gomez-Arostegui, H. (2010), “Prospective Compensation in Lieu of a Final Injunction in Patent and Copyright Cases”, *Fordham Law Review* 78(4), available at: <http://ir.lawnet.fordham.edu/flr/vol78/iss4/2>.
- Topol, E. J. (2019), “High-performance medicine: The convergence of human and artificial intelligence”, *Nature Medicine* 25: 44–56.
- Tripathi, P., Rawat, G., Yadav, S. and Saxena, R. K. (2015), “Shikimic acid, a base compound for the formulation of swine/avian flu drug: statistical optimization, fed-batch and scale up studies along with its application as an antibacterial agent”, *Antonie van Leeuwenhoek: Journal of Microbiology*, 107: 419–431.
- Trippe, A. (2015), *Guidelines for Preparing Patent Landscape Reports*, Geneva: WIPO.
- UNAIDS (2004), 2004 Report on the global AIDS epidemic, available at: http://files.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2004/GAR2004_en.pdf.
- UNAIDS (2006), *Courting Rights: Case Studies in Litigating the Human Rights of People Living with HIV*, available at: http://files.unaids.org/en/media/unaids/contentassets/dataimport/pub/report/2006/jc1189-courtingrights_en.pdf.
- UNAIDS, World Health Organization (WHO) and United Nations Development Programme (UNDP) (2011), “Using TRIPS Flexibilities to Improve Access to HIV Treatment”, Policy Brief, Geneva: UNAIDS, WHO and UNDP.
- Unitaid (2014a), *A Review of the Bedaquiline Patent Landscape: A Scoping Report*, Geneva: Unitaid Secretariat.
- Unitaid (2014b), *HIV/AIDS Diagnostics Technology Landscape*, 4th Edition, available at: https://unitaid.org/assets/UNITAID-HIV_Diagnostic_Landscape-4th_edition.pdf.
- Unitaid (2017), *Tuberculosis Diagnostics Technology Landscape*, 5th Edition, May 2017, available at: <https://unitaid.org/assets/2017-Unitaid-TB-Diagnostics-Technology-Landscape.pdf>.
- Unitaid and Medicines Patent Pool (2015), *Patents and Licences on Antiretrovirals: A Snapshot*, Geneva: Unitaid Secretariat.
- United Kingdom, Intellectual Property Office (IPO), Patent Informatics Team (2011), *Patent Thickets: An Overview: Subject to Peer Review*, Newport, UK: IPO.
- United Nations Conference on Trade and Development (UNCTAD) (2015a), The model law on competition, available at: <http://unctad.org/en/Pages/DITC/CompetitionLaw/The-Model-Law-on-Competition.aspx>.
- United Nations Conference on Trade and Development (UNCTAD) (2015b), The role of competition in the pharmaceutical sector and its benefits for consumers, TD/RBP/CONF.8/3.
- United Nations Development Programme (UNDP) (2014), *Using Competition Law to Promote Access to Health Technologies: A Guidebook for Low- and Middle-Income Countries*, online version, available at: <http://www.undp.org/content/undp/en/home/librarypage/hiv-aids/using-competition-law-to-promote-access-to-medicine.html>.
- United Nations Development Programme (UNDP) (2017), *Using Competition Law to Promote Access to Medicines and Related Health Technologies in Low- and Middle-Income Countries*, online version, available at: http://adphealth.org/upload/resource/Competition_Law_Issue_Brief_final_15Aug.pdf.
- United Nations Educational, Scientific and Cultural Organization (UNESCO), International Bioethics Committee (IBC) (2017), *Report of the IBC on Big Data and Health*, SHS/YES/IBC-24/17/3 REV.2, Paris: UNESCO.
- United Nations Environment Programme (UNEP) (2019), *Frontiers 2018/19: Emerging Issues of Environmental Concern*, Nairobi: UNEP, available at: <https://wedocs.unep.org/bitstream/handle/20.500.11822/27538/Frontiers1819.pdf?sequence=1&isAllowed=y>.
- United Nations International Children’s Emergency Fund (UNICEF) (2019), *Human Papillomavirus Vaccine: Supply and Demand Update*, December 2019, available at: <https://www.unicef.org/supply/media/501/file/humanpapillomavirusHPVvaccinesupplyanddemandupdate.pdf>.
- United States Congress, Congressional Budget Office (USCBO) (2006), *Research and Development in the Pharmaceutical Industry*, Washington, DC: USCBO.

- United States Congress, Office of Technology Assessment (1993), *Pharmaceutical R&D: Costs, Risks and Rewards*, OTA-H-522, Washington, DC: U.S. Government Printing Office.
- United States Federal Trade Commission (FTC) (2009), *Emerging Health Care Issues: Follow-on Biologic Drug Competition*, Washington, DC: FTC.
- United States Federal Trade Commission (FTC) (2017), *Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed in Fiscal Year 2015: A Report by the Bureau of Competition*, available at: <https://www.ftc.gov/reports/agreements-filed-federal-trade-commission-under-medicare-prescription-drug-improvement-9>.
- United States Federal Trade Commission (FTC) (2019), "Last Remaining Defendant Settles FTC Suit that Led to Landmark Supreme Court Ruling on Drug Company 'Reverse Payments'", press release, 28 February 2019, available at: <https://www.ftc.gov/news-events/press-releases/2019/02/last-remaining-defendant-settles-ftc-suit-led-landmark-supreme>.
- United States Food and Drug Administration (FDA) (2017a), FDA approval brings first gene therapy to the United States, press announcement, available at: <https://www.fda.gov/news-events/press-announcements/fda-approval-brings-first-gene-therapy-united-states>.
- United States Food and Drug Administration (FDA) (2017b), FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss, press announcement, available at: <https://www.fda.gov/news-events/press-announcements/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss>.
- United States Food and Drug Administration (FDA) (2018), FDA approves first generic version of EpiPen, press announcement, available at: <https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-version-epipen>.
- United States Food and Drug Administration (FDA) (2019a), *Advancing Health through Innovation: 2018 New Drug Therapy Approvals*, available at: <https://www.fda.gov/media/120357/download>.
- United States Food and Drug Administration (FDA) (2019b), *Considerations in Demonstrating Interchangeability with a Reference Product: Guidance for Industry*, Washington, DC: FDA.
- United States Government Accountability Office (2017), *Drug Industry: Profits, Research and Development Spending, and Merger and Acquisition Deals*, GAO-18-40, available at: <https://www.gao.gov/assets/690/688472.pdf>.
- United States Patent and Trademark Office (USPTO) (2001), "Final Guidelines for Determining Utility of Gene-Related Inventions", press release, 4 January 2001.
- United States Patent and Trademark Office (USPTO) (2018), *New PTAB Studies in AIA Proceedings: Expanded Panels and Trial Outcomes for Orange Book-listed Patents*, available at: https://www.uspto.gov/sites/default/files/documents/chat_with_the_chief_march_2018.pdf.
- United States Patent and Trademark Office (USPTO) (2019), Revised Patent Subject Matter Eligibility Guidance; issued 7 January 2019 and updated 17 October 2019, available at: <https://www.uspto.gov/patent/laws-and-regulations/examination-policy/subject-matter-eligibility>.
- Uzuner, H., Bauer, R., Fan, T. P., Guo, D. A., Diaz, A., El-Nezami, H. et al. (2012), "Traditional Chinese medicine research in the post-genomic era: Good practice, priorities, challenges and opportunities", *Journal of Ethnopharmacology* 140(3): 458–468.
- van den Ham, R., Bero, L. and Laing, R. (2011), *The World Medicines Situation 2011: Selection of Essential Medicines*, Geneva: WHO.
- van den Heuvel, R., Stirling, C., Kapadia, A., Zhou, J. (2018), *Medical Devices 2030: Making a power play to avoid the commodity trap*, KPMG, available at: <https://institutes.kpmg.us/content/dam/institutes/en/healthcare-life-sciences/pdfs/2018/medical-devices-2030.pdf>.
- van Luijn, J. C., Gribnau, F. W. and Leufkens, H. G. (2010), "Superior efficacy of new medicines?", *European Journal of Clinical Pharmacology*, 66(5): 445–448.
- Viergever, R. F. and Hendriks, T. C. C. (2016), "The 10 largest public and philanthropic funders of health research in the world: What they fund and how they distribute their funds", *Health Research Policy and Systems* 14: 12.
- Vitry, A. I., Shin, N. H. and Vitre, P. (2013), "Assessment of the therapeutic value of new medicines marketed in Australia", *Journal of Pharmaceutical Policy and Practice*, 6(1): 2.
- Vivot, A., Jacot, J., Zeitoun, J.-D., Ravaud, P., Crequit, P. and Porcher, R. (2017), "Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015", *Annals of Oncology*; 28: 1111–1116.
- Vogler, S. and Schneider, P. (2019), "Medicine Price Data Sources", in *Medicine Price Surveys, Analyses and Comparisons*, Vogler, S. (ed.), London: Academic Press.
- Vogler, S., Zimmermann, N., Habl, C., Piessnegger, J. and Bucsics, A. (2012), "Discounts and rebates granted to public payers for medicines in European countries", *Southern Medical Review* 5(1): 38–46.
- Von Der Ropp, A. and Taubman, T. (2006), "Bioethics and patent law: The case of Myriad", *WIPO Magazine* 4: 8–9.
- Vondeling, G. T., Cao, Q., Postma, M. J. and Rozenbaum, M. A. (2018), "The impact of patent expiry on drug prices: A systematic literature review", *Applied Health Economics and Health Policy* 16(5): 653–660.
- Wang, H., Sun, Q., Vitry, A. and Nguyen, T. A. (2017), "Availability, price, and affordability of selected essential medicines for chronic diseases in 11 countries of the Asia Pacific Region: A secondary analysis", *Asia Pacific Journal of Public Health*, 29(4), 268–277.
- Wang, H., Vinyals Torres, L., Travis, P. (2018), "Catastrophic health expenditure and financial protection in eight countries in the WHO South-East Asia Region", *Bulletin of the World Health Organization*, 96(9), 610–620E.
- Ward, A. (2015), "Medical Research Council faces budget crunch from 'patent cliff'", *Financial Times*, online version, 16 August 2015, available at: <https://www.ft.com/content/bdd435c6-4293-11e5-b98b-87c7270955cf>.
- Wasserman, E. (2016), "Takeda loses again to Hikma in gout drug patent battle", *FiercePharma*, online version, 24 May 2016.

- Watal, J. (2001), "Workshop on Differential Pricing and Financing of Essential Drugs: Background Note Prepared by Jayashree Watal, Consultant to the WTO Secretariat", Geneva: WTO.
- Watal, J. and Dai, R. (2019), "Product Patents and Access to Innovative Medicines in a Post-TRIPS-Era", Staff Working Paper ERSD-2019-05, Geneva: WTO.
- Weires, R. (2019), "Recent advances in biologics manufacturing diminish the importance of trade secrets: a response to Price and Rai", *Written Description*, 4 March 2019.
- Welch, A. R. (2016a), "The Norwegian biosimilar phenomenon: From biosimilar to 'biogeneric'", *Biosimilar Development*, online version, 26 July 2016.
- Welch, A. R. (2016b), "What to know about emerging market biosimilar pathways", *Biosimilar Development*, online version, 24 June 2016.
- Wendland, W. and Jiao, F. (2018), "Intellectual Property Rights and Traditional Medical Knowledge in Africa: Issues and Development", in Wambebe, C. (ed.), *African Indigenous Medical Knowledge and Human Health: Research, Development, and Delivery*, Boca Raton (FL): CRC Press.
- West, D. M., Villasenor, J. and Schneider, J. (2017), *Private Sector Investment in Global Health R&D: Spending Levels, Barriers and Opportunities*, Washington, DC: The Brookings Institution.
- Wieseler, B., McGauran, N. and Kaiser, T. (2019), "New drugs: where did we go wrong and what can we do better?", *BMJ* 366: 14340.
- Williams, H. L. (2017), "How do patents affect research investments?", *Annual Review of Economics* 9: 441–469.
- Wingrove, J. (2019), "SPC waiver may drive innovator investment in secondary patents and litigation", *Patent Strategy*, online version, 9 May 2019, available at: <https://patentstrategy.managingip.com/Articles/38>.
- Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., et al. (2017), "Essential medicines for universal health coverage", *The Lancet* 389(10067): 403–476.
- Workman, P., Draetta, G. F., Schellens, J. H. M. and Bernards, R. (2017), "How much longer will we put up with \$100,000 cancer drugs?", *Cell* 168(4): 579–583.
- World Bank (2005), *A Guide to Competitive Vouchers in Health*, Washington, DC: World Bank.
- World Bank (2009), "Europe and Central Asia: Health Insurance and Competition", Report No. 44316-ECA, Washington, DC: World Bank.
- World Health Organization (WHO) (2000), *The World Health Report 2000: Health Systems: Improving Performance*, Geneva: WHO.
- World Health Organization (WHO) (2001a), *Macroeconomics and Health: Investing in Health for Economic Development: Report of the Commission on Macroeconomics and Health*, Geneva: WHO.
- World Health Organization (WHO) (2001b), "Drug procurement: The principles for getting it right", *Essential Drugs Monitor* 30: 13–16.
- World Health Organization (WHO) (2001c), *How to Develop and Implement a National Drug Policy*, 2nd Edition, Geneva: WHO.
- World Health Organization (WHO) (2003a), "How to Develop and Implement a National Drug Policy", Policy Perspectives on Medicines 6.
- World Health Organization (WHO) (2003b), *Medical Device Regulations: Global Overview and Guiding Principles*, Geneva: WHO.
- World Health Organization (WHO) (2003c), "The Selection and Use of Essential Medicines: Report of the WHO Expert Committee 2002, including the 12th Model List of Essential Medicines," Technical Report Series 914, Geneva: WHO.
- World Health Organization (WHO) (2004), "Equitable Access to Essential Medicines: A Framework for Collective Action", Policy Perspectives on Medicines 8, Geneva: WHO.
- World Health Organization (WHO) (2005), "Remuneration Guidelines for Non-Voluntary Use of a Patent on Medical Technologies", Health Economics and Drugs TCM Series No. 18, Geneva: WHO.
- World Health Organization (WHO) (2006a), *Public Health, Innovation and Intellectual Property Rights: Report of the Commission on Intellectual Property Rights, Innovation and Public Health*, Geneva: WHO.
- World Health Organization (WHO) (2006b), "WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fortieth Report", Technical Report Series 937, Geneva: WHO.
- World Health Organization (WHO) (2007a), *Everybody's Business: Strengthening Health Systems to Improve Health Outcomes: WHO's Framework for Action*, Geneva: WHO.
- World Health Organization (WHO) (2007b), *WHO Model List of Essential Medicines for Children: 1st List, October 2007*, Geneva: WHO.
- World Health Organization (WHO) (2009a), Expert Committee on Biological Standardization, Geneva, 19 to 23 October 2009, "Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs)", available at: https://www.who.int/biologicals/publications/trs/areas/biological_therapeutics/TRS_977_Annex_2.pdf?ua=1.
- World Health Organization (WHO) (2009b), *Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks*, Geneva: WHO.
- World Health Organization (WHO) (2010), *Assessment of Medicines Regulatory Systems in Sub-Saharan African Countries: An Overview of Findings from 26 Assessment Reports*, Geneva: WHO.
- World Health Organization (WHO) (2011a), *Increasing Access to Vaccines Through Technology Transfer and Local Production*, Geneva: WHO.
- World Health Organization (WHO) (2011b), *Local Production for Access to Medical Products: Developing a Framework to Improve Public Health*, Geneva: WHO.
- World Health Organization (WHO) (2011c), *Pandemic Influenza Preparedness Framework for the Sharing of Influenza Viruses and Access to Vaccines and Other Benefits*, Geneva: WHO.
- World Health Organization (WHO) (2011d), "WHO's role in the prevention and control of medical products of compromised

quality, safety and efficacy such as substandard/spurious/falsely-labelled/falsified/counterfeit medical products" (A/SSFFC/WG/3 Rev.1), 17 February 2011.

World Health Organization (WHO) (2012), *Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination: Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination*, Geneva: WHO.

World Health Organization (WHO) (2013a), *Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020*, Geneva: WHO, available at: https://apps.who.int/iris/bitstream/handle/10665/94384/9789241506236_eng.pdf?sequence=1.

World Health Organization (WHO) (2013b), *Weekly Epidemiological Record* 1(88): 1–16, available at: <https://www.who.int/wer/2013/wer8801.pdf?ua=1> www.who.int/immunization_delivery/new_vaccines/technologies_aerosol/en/.

World Health Organization (WHO) (2014a), *Access to Antiretroviral Drugs in Low- and Middle-Income Countries*, Technical Report, Geneva: WHO.

World Health Organization (WHO) (2014b), *Guidelines for the Screening, Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection*, Geneva: WHO.

World Health Organization (WHO) (2014c), *Hepatitis E Vaccine: Composition, Safety, Immunogenicity and Efficacy, A document prepared for Strategic Advisory Group of Experts on Immunization (SAGE) by the Hepatitis E Vaccine Working Group*, available at: https://www.who.int/immunization/sage/meetings/2014/october/2_HepEvaccsafety_immunogenicity_efficiency_final_1Oct2014.pdf.

World Health Organization (WHO) (2014d), *Increasing Access to HIV Treatment in Middle-Income Countries: Key Data on Prices, Regulatory Status, Tariffs and the Intellectual Property Situation*, Geneva: WHO.

World Health Organization (WHO) (2015a), *Access to New Medicines in Europe: Technical Review of Policy Initiatives and Opportunities for Collaboration and Research*, Copenhagen: WHO Regional Office for Europe.

World Health Organization (WHO) (2015b), *Health in 2015 from MDGs Millennium Development Goals to SDGs Sustainable Development Goals*, Geneva: WHO.

World Health Organization (WHO) (2015c), "The Selection and Use of Essential Medicines: Report of the WHO Expert Committee 2015 (including the 19th WHO Model List of Essential Medicines and the 5th WHO Model List of Essential Medicines for Children", Technical Report Series No. 994, Geneva: WHO.

World Health Organization (WHO) (2015d), *Trade and Health: Towards Building a National Strategy*, Smith, R., Blouin, C., Mirza, Z., Beyer, P. and Drager, N. (eds.), Geneva: WHO.

World Health Organization (WHO) (2015e), *WHO Guideline on Country Pharmaceutical Pricing Policies*, Geneva: WHO.

World Health Organization (WHO) (2015f), "WHO Statement on Public Disclosure of Clinical Trial Results", 9 April 2015, available at: www.who.int/ictrp/results/reporting/en/.

World Health Organization (WHO) (2016a), *Global Report on Access to Hepatitis C Treatment: Focus on Overcoming Barriers*, Geneva: WHO.

World Health Organization (WHO) (2016b), *The Role of Intellectual Property in Local Production in Developing Countries: Opportunities and Challenges*, Geneva: WHO.

World Health Organization (WHO) (2016c), *WHO Treatment Guidelines for Drug-Resistant Tuberculosis: 2016 Update: October 2016 Revision*, Geneva: WHO.

World Health Organization (WHO) (2016d), "WHO updates patent information on treatment of Hepatitis C", online version.

World Health Organization (WHO) (2016e), *Working for Health and Growth: Investing in the Health Workforce: Report of the High-Level Commission on Health Employment and Economic Growth*, Geneva: WHO.

World Health Organization (WHO) (2017a), *Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline, Including Tuberculosis*, Geneva: WHO.

World Health Organization (WHO) (2017b), *Global Atlas of Medical Devices*. WHO Medical Devices Technical Series, Geneva: WHO.

World Health Organization (WHO) (2017c), *Global Hepatitis Report 2017*, Geneva: WHO.

World Health Organization (WHO) (2017d), *Integrating Neglected Tropical Diseases into Global Health and Development: Fourth WHO Report on Neglected Tropical Diseases*, Geneva: WHO, available at: <https://apps.who.int/iris/bitstream/handle/10665/255011/9789241565448-eng.pdf?sequence=1>.

World Health Organization (WHO) (2017e), "Overall programme review of the global strategy and plan of action on public health, innovation and intellectual property. Report of the review panel. November 2017".

World Health Organization (WHO) (2017f), "The Selection and Use of Essential Medicines: Report of the WHO Expert Committee 2017 (including the 20th WHO Model List of Essential Medicines and the 6th WHO Model List of Essential Medicines for Children", Technical Report Series No. 1006, Geneva: WHO.

World Health Organization (WHO) (2017g), *A Study on the Public Health and Socioeconomic Impact of Substandard and Falsified Medical Products*, Geneva: WHO.

World Health Organization (WHO) (2017h), *Together on the Road to Universal Health Coverage: A Call to Action*, Geneva: WHO.

World Health Organization (WHO) (2017i), "Transition to New Antiretrovirals", HIV Treatment Policy Brief, Geneva: WHO.

World Health Organization (WHO) (2017j), *WHO Global Model Regulatory Framework for Medical Devices including in vitro diagnostic medical devices*, Medical Device Technical Series, Geneva: WHO.

World Health Organization (WHO) (2017k), *WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products*, Geneva: WHO.

World Health Organization (WHO) (2017l), "WHO to begin pilot prequalification of biosimilars for cancer treatment", 4 May 2017.

World Health Organization (WHO) (2018a), "Approaches to Seasonal Influenza and Genetic Sequence Data under the PIP Framework", 14 December 2018.

- World Health Organization (WHO) (2018b), *Assessing National Capacity for the Prevention and Control of Noncommunicable Diseases: Report of the 2017 Global Survey*, Geneva: WHO.
- World Health Organization (WHO) (2018c), *Facilitating Access and Benefit-Sharing (ABS) for Pathogens to Support Public Health: Workshop Report: 11–12 June 2018 Workshop*, September 2018, Geneva: WHO.
- World Health Organization (WHO) (2018d), *Global Vaccine Action Plan: Monitoring, Evaluation & Accountability: Secretariat Annual Report 2018*, Geneva: WHO.
- World Health Organization (WHO) (2018e), *Progress Report on Access to Hepatitis C Treatment: Focus on Overcoming Barriers in Low- and Middle-income Countries*, Geneva: WHO.
- World Health Organization (WHO) (2018f), *Rapid Communication: Key Changes to Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis (MDR/RR-TB)*, Geneva: WHO.
- World Health Organization (WHO) (2018g), *Technical Report: Pricing of Cancer Medicines and Its Impacts: A Comprehensive Technical Report for the World Health Assembly Resolution 70.12: Operative Paragraph 2.9 on Pricing Approaches and Their Impacts on Availability and Affordability of Medicines for the Prevention and Treatment of Cancer*. Geneva: WHO, available at: <https://apps.who.int/iris/bitstream/handle/10665/277190/9789241515115-eng.pdf?ua=1>.
- World Health Organization (WHO) (2018h), *Updated Recommendations on First-Line and Second-Line Antiretroviral Regimens and Post-Exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV: Interim Guidelines: Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection*, Geneva: WHO.
- World Health Organization (WHO) (2018i), WHO EML cancer medicines working group (CMWG): report of the meeting 22-23 March 2018, Geneva, Switzerland. Geneva: WHO, available at: <https://apps.who.int/iris/bitstream/handle/10665/272962/WHO-EMP-IAU-2018.03-eng.pdf?sequence=1&isAllowed=y>.
- World Health Organization (WHO) (2019a), *Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline*, Geneva: WHO.
- World Health Organization (WHO) (2019b), *Executive Summary: The Selection and Use of Essential Medicines 2019: Report of the 22nd WHO Expert Committee on the Selection and Use of Essential Medicines, 1–5 April 2019*, Geneva: WHO.
- World Health Organization (WHO) (2019c), *Global Tuberculosis Report 2019*, Geneva: WHO.
- World Health Organization (WHO) (2019d), *Pandemic Influenza Preparedness Framework: Annual Progress Report 1 January–31 December 2018*, Geneva: WHO.
- World Health Organization (WHO) (2019e), “Universal health coverage (UHC)”, 24 January 2019.
- World Health Organization (WHO) (2019f), *WHO Global Report on Traditional and Complementary Medicine*, Geneva: WHO.
- World Health Organization (WHO) and Health Action International (HAI) (2008), *Measuring Medicine Prices, Availability, Affordability and Price Components*, Geneva and Amsterdam: WHO and HAI.
- World Health Organization (WHO) and International Bank for Reconstruction and Development / The World Bank (2020), *Global Monitoring Report on Financial Protection in Health 2019*, Geneva: WHO.
- World Health Organization (WHO) and UNAIDS (2000), Patent situation of HIV/AIDS-related drugs in 80 countries, available at: <https://www.who.int/3by5/en/patentsshivdrugs.pdf>.
- World Health Organization (WHO) and World Trade Organization (WTO) (2002), *WTO Agreements & Public Health: A Joint Study by the WHO and the WTO Secretariat*, Geneva: WHO and WTO.
- World Health Organization (WHO), Market Information for Access to Vaccines (MI4A) and WHO Vaccine Product, Price and Procurement (V3P) (2018), *Global Vaccine Market Report*, available at: https://www.who.int/immunization/programmes_systems/procurement/v3p/platform/module2/MI4A_Global_Vaccine_Market_Report.pdf?ua=1.
- World Health Organization (WHO) Regional Office for Europe (2019), *Can people afford to pay for health care? New evidence on financial protection in Europe*, Copenhagen: WHO Regional Office for Europe.
- World Intellectual Property Organization (WIPO) (2001), *Intellectual Property Needs and Expectations of Traditional Knowledge Holders: WIPO Report on Fact-Finding Missions on Intellectual Property and Traditional Knowledge (1998–1999)*, Geneva: WIPO.
- World Intellectual Property Organization (WIPO) (2007), *The 45 Adopted Recommendations under the WIPO Development Agenda*, available at www.wipo.int/ip-development/en/agenda/recommendations.html.
- World Intellectual Property Organization (WIPO) (2009), *The Economics of Intellectual Property: Suggestions for Further Research in Developing Countries and Countries with Economies in Transition*, Geneva: WIPO.
- World Intellectual Property Organization (WIPO) (2011a), “WIPO Patent Search Report on Pandemic Influenza Preparedness (PIP)-Related Patents and Patent Applications”, Geneva: WIPO.
- World Intellectual Property Organization (WIPO) (2011b), *World Intellectual Property Report: The Changing Face of Innovation*, Geneva: WIPO.
- World Intellectual Property Organization (WIPO) (2014a), *Alternatives in Patent Search and Examination: Policy Guide*, Geneva: WIPO.
- World Intellectual Property Organization (WIPO) (2014b), “Patent Pools and Antitrust – A Comparative Analysis”, Geneva: WIPO.
- World Intellectual Property Organization (WIPO) (2015a), *Intellectual Property and Genetic Resources, Traditional Knowledge and Traditional Cultural Expressions: Overview*, Geneva: WIPO.
- World Intellectual Property Organization (WIPO) (2015b), *WIPO Guide to Using Patent Information*, Geneva: WIPO.
- World Intellectual Property Organization (WIPO) (2015c), *World Intellectual Property Report: Breakthrough Innovation and Economic Growth*, Geneva: WIPO.
- World Intellectual Property Organization (WIPO) (2017a), *Documenting Traditional Knowledge – A Toolkit*, Geneva: WIPO.
- World Intellectual Property Organization (WIPO) (2017b), *Key Questions on Patent Disclosure Requirements for Genetic Resources and Traditional Knowledge*, Geneva: WIPO.

- World Intellectual Property Organization (WIPO) (2017c), *Protect and Promote Your Culture: A Practical Guide to Intellectual Property for Indigenous Peoples and Local Communities*, Geneva: WIPO, 2017.
- World Intellectual Property Organization (WIPO) (2018), *World Intellectual Property Indicators 2018*, Geneva: WIPO.
- World Intellectual Property Organization (WIPO) (2019a), *Patent Cooperation Treaty Yearly Review 2019: The International Patent System*, Geneva: WIPO.
- World Intellectual Property Organization (WIPO) (2019b), *WIPO Technology Trends 2019: Artificial Intelligence*, Geneva: WIPO.
- World Medical Association (WMA) (2013), *WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects*.
- World Trade Organization (WTO) (2011), *World Trade Report 2011: The WTO and Preferential Trade Agreements: From Co-existence to Coherence*, Geneva: WTO.
- World Trade Organization (WTO) (2012), *A Handbook on the WTO TRIPS Agreement*, Taubman, A., Wager, H. and Watal, J. (eds.), New York: Cambridge University Press.
- World Trade Organization (WTO) (2018), *Mainstreaming Trade to Attain the Sustainable Development Goals*, Geneva: WTO.
- Wouters, O. J., Kanavos, P. G. and McKee, M. (2017), “Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes and Spending”, *Millbank Quarterly* 95(3): 554-601.
- Wouters, O. J., Sandberg, D. M., Pillay, A. and Kanavos, P. G. (2019), “The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period”, *Social Science & Medicine* 220: 362–370.
- Yadav, P. (2010), *Differential Pricing for Pharmaceuticals: Review of Current Knowledge, New Findings and Ideas for Action: A study conducted for the UK Department for International Development (DFID)*, Zaragoza.
- Yamane, H. (2011), *Interpreting TRIPS: Globalisation of Intellectual Property Rights and Access to Medicines*, Oxford and Portland (OR): Hart Publishing.
- Young, R., Bekele, T., Gunn, A., Chapman, N., Chowdhary, V., Corrigan, K. et al. (2018), “Developing new health technologies for neglected diseases: A pipeline portfolio review and cost model”, *Gates Open Research* 2: 23.
- Zain, S. (2014), “Antitrust Liability for Maintaining Baseless Litigation”, *Santa Clara Law Review* 54(3): 729–759, available at: <http://digitalcommons.law.scu.edu/lawreview/vol54/iss3/5>.
- Ziegler, N. Gassmann, O. and Friesike, S. (2014), “Why do firms give away their patents for free?”, *World Patent Information* 37: 19–25.